<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Genome Med</journal-id>
        <journal-id journal-id-type="iso-abbrev">Genome Med</journal-id>
        <journal-id journal-id-type="pmc-domain-id">863</journal-id>
        <journal-id journal-id-type="pmc-domain">genmed</journal-id>
        <journal-title-group>
          <journal-title>Genome Medicine</journal-title>
        </journal-title-group>
        <issn pub-type="epub">1756-994X</issn>
        <publisher>
          <publisher-name>BMC</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC5180407</article-id>
        <article-id pub-id-type="pmcid-ver">PMC5180407.1</article-id>
        <article-id pub-id-type="pmcaid">5180407</article-id>
        <article-id pub-id-type="pmcaiid">5180407</article-id>
        <article-id pub-id-type="pmid">28007021</article-id>
        <article-id pub-id-type="doi">10.1186/s13073-016-0389-6</article-id>
        <article-id pub-id-type="publisher-id">389</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Research</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" equal-contrib="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9135-3391</contrib-id>
            <name name-style="western">
              <surname>Oberg</surname>
              <given-names initials="JA">Jennifer A.</given-names>
            </name>
            <address>
              <email>jao37@columbia.edu</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name name-style="western">
              <surname>Glade Bender</surname>
              <given-names initials="JL">Julia L.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <name name-style="western">
              <surname>Sulis</surname>
              <given-names initials="ML">Maria Luisa</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Pendrick</surname>
              <given-names initials="D">Danielle</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sireci</surname>
              <given-names initials="AN">Anthony N.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hsiao</surname>
              <given-names initials="SJ">Susan J.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Turk</surname>
              <given-names initials="AT">Andrew T.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dela Cruz</surname>
              <given-names initials="FS">Filemon S.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
            <xref ref-type="aff" rid="Aff7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hibshoosh</surname>
              <given-names initials="H">Hanina</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Remotti</surname>
              <given-names initials="H">Helen</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zylber</surname>
              <given-names initials="RJ">Rebecca J.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Pang</surname>
              <given-names initials="J">Jiuhong</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Diolaiti</surname>
              <given-names initials="D">Daniel</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Koval</surname>
              <given-names initials="C">Carrie</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Andrews</surname>
              <given-names initials="SJ">Stuart J.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Garvin</surname>
              <given-names initials="JH">James H.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Yamashiro</surname>
              <given-names initials="DJ">Darrell J.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chung</surname>
              <given-names initials="WK">Wendy K.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Emerson</surname>
              <given-names initials="SG">Stephen G.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff4">4</xref>
            <xref ref-type="aff" rid="Aff5">5</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nagy</surname>
              <given-names initials="PL">Peter L.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mansukhani</surname>
              <given-names initials="MM">Mahesh M.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <name name-style="western">
              <surname>Kung</surname>
              <given-names initials="AL">Andrew L.</given-names>
            </name>
            <address>
              <email>kunga@mskcc.org</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
            <xref ref-type="aff" rid="Aff6">6</xref>
            <xref ref-type="aff" rid="Aff7">7</xref>
          </contrib>
          <aff id="Aff1"><label>1</label>Department of Pediatrics, Columbia University Medical Center, New York, NY 10032 USA </aff>
          <aff id="Aff2"><label>2</label>Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032 USA </aff>
          <aff id="Aff3"><label>3</label>Department of Clinical Genetics, Columbia University Medical Center, New York, NY 10032 USA </aff>
          <aff id="Aff4"><label>4</label>Department of Medicine, Columbia University Medical Center, New York, NY 10032 USA </aff>
          <aff id="Aff5"><label>5</label>Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY 10032 USA </aff>
          <aff id="Aff6"><label>6</label>Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032 USA </aff>
          <aff id="Aff7"><label>7</label>Present address: Memorial Sloan Kettering Cancer Center, New York, NY 10065 USA </aff>
          <aff id="Aff8"><label>8</label>Present address: MNG Laboratories, 5424 Glenridge Drive, Atlanta, GA 30342 USA </aff>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>23</day>
          <month>12</month>
          <year>2016</year>
        </pub-date>
        <pub-date pub-type="collection">
          <year>2016</year>
        </pub-date>
        <volume>8</volume>
        <issue-id pub-id-type="pmc-issue-id">262910</issue-id>
        <elocation-id>133</elocation-id>
        <history>
          <date date-type="received">
            <day>1</day>
            <month>7</month>
            <year>2016</year>
          </date>
          <date date-type="accepted">
            <day>2</day>
            <month>12</month>
            <year>2016</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>23</day>
              <month>12</month>
              <year>2016</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>28</day>
              <month>12</month>
              <year>2016</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-03-25 11:25:27.620">
              <day>25</day>
              <month>03</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© The Author(s). 2016</copyright-statement>
          <license license-type="OpenAccess">
            <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13073_2016_Article_389.pdf"/>
        <abstract id="Abs1">
          <sec>
            <title>Background</title>
            <p>Molecular characterization has the potential to advance the management of pediatric cancer and high-risk hematologic disease. The clinical integration of genome sequencing into standard clinical practice has been limited and the potential utility of genome sequencing to identify clinically impactful information beyond targetable alterations has been underestimated.</p>
          </sec>
          <sec>
            <title>Methods</title>
            <p>The Precision in Pediatric Sequencing (PIPseq) Program at Columbia University Medical Center instituted prospective clinical next generation sequencing (NGS) for pediatric cancer and hematologic disorders at risk for treatment failure. We performed cancer whole exome sequencing (WES) of patient-matched tumor-normal samples and RNA sequencing (RNA-seq) of tumor to identify sequence variants, fusion transcripts, relative gene expression, and copy number variation (CNV). A directed cancer gene panel assay was used when sample adequacy was a concern. Constitutional WES of patients and parents was performed when a constitutionally encoded disease was suspected. Results were initially reviewed by a molecular pathologist and subsequently by a multi-disciplinary molecular tumor board. Clinical reports were issued to the ordering physician and posted to the patient’s electronic medical record.</p>
          </sec>
          <sec>
            <title>Results</title>
            <p>NGS was performed on tumor and/or normal tissue from 101 high-risk pediatric patients. Potentially actionable alterations were identified in 38% of patients, of which only 16% subsequently received matched therapy. In an additional 38% of patients, the genomic data provided clinically relevant information of diagnostic, prognostic, or pharmacogenomic significance. RNA-seq was clinically impactful in 37/65 patients (57%) providing diagnostic and/or prognostic information for 17 patients (26%) and identified therapeutic targets in 15 patients (23%). Known or likely pathogenic germline alterations were discovered in 18/90 patients (20%) with 14% having germline alternations in cancer predisposition genes. American College of Medical Genetics (ACMG) secondary findings were identified in six patients.</p>
          </sec>
          <sec>
            <title>Conclusions</title>
            <p>Our results demonstrate the feasibility of incorporating clinical NGS into pediatric hematology-oncology practice. Beyond the identification of actionable alterations, the ability to avoid ineffective/inappropriate therapies, make a definitive diagnosis, and identify pharmacogenomic modifiers is clinically impactful. Taking a more inclusive view of potential clinical utility, 66% of cases tested through our program had clinically impactful findings and samples interrogated with both WES and RNA-seq resulted in data that impacted clinical decisions in 75% of cases.</p>
          </sec>
          <sec>
            <title>Electronic supplementary material</title>
            <p>The online version of this article (doi:10.1186/s13073-016-0389-6) contains supplementary material, which is available to authorized users.</p>
          </sec>
        </abstract>
        <kwd-group xml:lang="en">
          <title>Keywords</title>
          <kwd>Whole exome sequencing</kwd>
          <kwd>RNA sequencing</kwd>
          <kwd>Precision medicine</kwd>
          <kwd>Pediatric oncology</kwd>
        </kwd-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008258</institution-id>
                <institution>Hyundai Hope On Wheels</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001445</institution-id>
                <institution>Alex's Lemonade Stand Foundation for Childhood Cancer</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100002275</institution-id>
                <institution>Pediatric Cancer Foundation</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
          <award-group>
            <funding-source>
              <institution>Taybandz/ Conquering Kidz Cancer</institution>
            </funding-source>
          </award-group>
          <award-group>
            <funding-source>
              <institution>Jamie Deutsch Foundation</institution>
            </funding-source>
          </award-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100002344</institution-id>
                <institution>Ira Sohn Research Conference Foundation</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
          <award-group>
            <funding-source>
              <institution>Hope and Heroes</institution>
            </funding-source>
          </award-group>
          <award-group>
            <funding-source>
              <institution>Herbert Irving Comprehensive Cancer Center</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>issue-copyright-statement</meta-name>
            <meta-value>© The Author(s) 2016</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec id="Sec1" sec-type="introduction">
        <title>Background</title>
        <p>The outcomes for children with cancer have steadily improved to the present time when more than 80% of all pediatric oncology patients are cured [<xref ref-type="bibr" rid="CR1">1</xref>]. Nonetheless, cancer remains the leading cause of disease-related death in children. Moreover, this success has come at a price; two-thirds of all survivors have some long-term sequelae attributable to their treatment [<xref ref-type="bibr" rid="CR2">2</xref>]. Together, the requirement to further improve existing outcomes and to decrease toxicity underscores the need for the current national initiative in precision medicine to include pediatric oncology patients.</p>
        <p>Many of the advances in pediatric oncology have resulted from the implementation of risk-stratified treatment strategies that incorporate histological, anatomical, and molecular prognostic and predictive determinants into the choice of therapies for individual patients [<xref ref-type="bibr" rid="CR3">3</xref>]. Changes in ploidy, chromosomal segmental changes, and specific gene alterations are routinely utilized to guide treatment intensity in pediatric oncology [<xref ref-type="bibr" rid="CR4">4</xref>]. Therefore, the tenants of precision medicine are intrinsic to the practice of pediatric oncology.</p>
        <p>Recent advances in massively parallel sequencing allow for more comprehensive approaches to determine the abnormalities contributing to tumorigenesis. Initial implementation of next generation sequencing (NGS) technologies focused on the identification of actionable alterations, with estimates in the range of 5% to nearly 100% depending on disease histology and evolving definitions of “actionable” [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR15">15</xref>]. The utility of these technologies, however, extends well beyond the identification of actionable alterations and determining the value of these technologies should be more inclusive and consider the broad clinical impact of testing.</p>
        <p>In 2014, we implemented a clinical NGS platform for pediatric oncology patients. The Precision in Pediatric Sequencing (PIPseq) Program utilizes NGS of tumor and germline in a CLIA-certified (Clinical Laboratory Improvement Amendments of 1988) environment and includes interrogation of both DNA and RNA. We conducted a retrospective review of our first 101 consecutively sequenced patients utilizing the PIPseq pipeline and report here our experience with integrating clinical NGS into pediatric hematology-oncology practice and describe the broad clinical utility of genomically informed cancer medicine.</p>
      </sec>
      <sec id="Sec2" sec-type="materials|methods">
        <title>Methods</title>
        <sec id="Sec3">
          <title>The PIPseq pipeline</title>
          <p>To achieve more comprehensive genome-level analysis in our pediatric oncology patients, we utilized three CLIA-certified, CAP (College of American Pathologists), and New York State Department of Health approved assays. When possible, we utilized a cancer whole exome sequencing test (cWES) comprising WES of tumor and normal tissue (buccal swab or peripheral blood) and RNA sequencing (RNA-seq) of tumor tissue. This assay was optimized for fresh or frozen specimens. When sample adequacy was a concern, we also utilized a directed cancer gene panel assay which sequenced 467 cancer-associated genes and was optimized for use with formalin fixed paraffin embedded (FFPE) material (Columbia Comprehensive Cancer Panel, CCCP). If a constitutionally encoded disease was suspected (e.g. familial hemophagocytic lymphohistiocytosis), we performed constitutional WES from the patient and both parents (trio) when available.</p>
          <p>Tissue for sequencing was obtained either from archived blocks (FFPE) or frozen tissue blocks from the Department of Pathology. DNA and RNA extraction and sequencing were performed in a CLIA-certified laboratory. Variant calls were independently made on tumor and germline material and somatic variants determined by subtraction. Copy number variation (CNV) was determined from the WES data, fusion transcripts were identified from the RNA-seq data, and relative gene expression was determined by comparison to a model built from 124 transcriptomes. A mix of tissues was used to generate the model including normal white blood cells, lung, liver, brain, glioma, and cell lines.</p>
          <p>After initial review by a molecular pathologist, all results were reviewed in a multi-disciplinary molecular tumor board. Participants included representation by molecular pathology, pediatric oncology, cytogenetics, medical genetics, and cancer biology. For each patient, a report was issued containing variant calls, CNV, fusions, and overexpressed genes. Variants were assigned a tier based on disease-association and separately a tier based on level of evidence for clinical actionability (described below). Reports were delivered to ordering oncologists and posted to the electronic medical record (EMR) in accordance with patient opt-in/opt-out preferences selected at the time of informed consent.</p>
        </sec>
        <sec id="Sec4">
          <title>Patients and informed consent for clinical sequencing</title>
          <p>Between January 2014 and April 2016, NGS was performed on tumor and/or normal tissue from 101 high-risk patients by the Laboratory of Personalized Genomic Medicine at Columbia University Medical Center (CUMC). This represented approximately 32% of the total patients in our clinical practice. High-risk patients were defined as those having a prognosis of &lt;50% overall survival at 5 years, outlier clinical phenotype, rare cancer without standard of care therapy, suspected cancer predisposition, or relapsed disease. A request for constitutional WES, cWES and RNA-seq, or targeted cancer panel testing was made at the discretion of the referring oncologist in consultation with the PIPseq team [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
          <p>Participants signed consent for WES or cWES either as part of an Institutional Review Board (IRB)-approved protocol (IRB nos. AAAB7109, AAAJ5811) or they signed the clinical consent (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pathology.columbia.edu/diagnostic/PGM/oncologytests.html">http://pathology.columbia.edu/diagnostic/PGM/oncologytests.html</ext-link>). Written consent for clinical WES and cWES testing was obtained after the risks and benefits had been explained to the patient and/or caregiver, which include the potential disclosure of medically actionable secondary findings, defined as germline disease-causing mutations unrelated to the condition for which sequencing was being performed. Patients could opt in or opt out of the following: learning secondary findings and/or having these results appear in the EMR; having their samples and/or data stored for future research, both with or without identifiers; and future contact. Results not reported included carrier status, variants of uncertain significance (VOUS) in secondary findings except as related to cancer, and mutations related to adult-onset conditions for which the genetic link is either unclear or for which no known intervention is of proven benefit (e.g. Alzheimer’s disease). IRB approval was obtained for this retrospective analysis of de-identified patient and clinical genomics data (IRB nos. AAAP1200 and AAAQ8170).</p>
        </sec>
        <sec id="Sec5">
          <title>Clinical sequencing</title>
          <p>Testing required at least 200 ng of DNA for WES, at least 50 ng of DNA for targeted DNA sequencing, and at least 3000 ng of RNA for transcriptome analysis (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: DNA and RNA extraction). The entire assay was a CLIA-certified assay. The laboratory-developed test used general purpose reagents and the Agilent WES ver.5 + UTR baits. Specifically, WES was performed using the Agilent SureSelectXT All Exon V5 + UTRs capture kit for library generation and sequenced on the HiSeq2500 using paired-end 125 cycle × 2 sequencing (two tumors, two normal and two transcriptomes, pooled together and run in two lanes). Targeted DNA sequencing was performed on a 5.59 Mb Custom Agilent SureSelectXT library, targeting 467 genes, and sequenced on a HiSeq2500 using paired-end 125 cycle × 2 sequencing (seven samples per lane). RNA was sequenced using the TruSeq Stranded Total RNA LT Sample Prep Kit with 125 cycles × 2 paired-end sequencing on the HiSeq2500.</p>
        </sec>
        <sec id="Sec6">
          <title>Sequencing analysis</title>
          <p>DNA sequencing reads were de-multiplexed and converted to fastq files using CASAVA from Illumina. Mapping and variant calling of tumor and normal samples was performed using NextGene (v.2.3.4; Softgenetics, State College, PA, USA), which uses a modified Burrows-Wheeler transform (BWT) alignment method. Sequences were mapped to GRCh37 (“hg19”), retaining reads with a median quality score of 20 or higher, with no more than three ambiguous bases, a minimum number of 25 called bases per read, and trimming reads when three consecutive reads fell below a quality score of 16. Alignment and variant calling was performed using paired-end reads with a minimum of 10 reads, at least three variant reads, and a minimum variant allelic fraction of 10% for tumor and 5% for normal was required to call a variant. The variant calling module was set to “detect large indels.” The variant calling algorithm showed a 99.6% agreement with single nucleotide polymorphisms on an oligonucleotide microarray and over 96% sensitivity in inter-laboratory comparison and a 96% detection rate for heterozygous variants in a 40/60% mixture of samples. For small indels, the lab detected 93% of all variants detected by another laboratory in inter-laboratory comparison, with the greatest disagreement in insertions greater than 10 bp.</p>
          <p>Variants were subject to filtering. In normal DNA, variants were passed through a “reference range filter” of cancer predisposition genes, genes relevant to pharmacogenomics, and variants relevant to patient care; a “reportable range filter” which includes COSMIC (cosmic70 provided by Annovar) variants in the patient’s mutation report file and variants in genes recommended by the American College of Medical Genetics (ACMG) for the reporting of secondary findings [<xref ref-type="bibr" rid="CR17">17</xref>]; as well as a frequency filter, which includes variants whose minor allele frequency in the 1000 Genomes (phase 1, version 3, release date 23 November 2010) is less than 1%. Somatic mutations in the tumor were identified by subtracting all variants called in normal tissue (output at minor allelic fraction of ≥5%) from variants called in the tumor (output at a minor allelic fraction of ≥10%). The approach maximized the number of variants output to minimize the likelihood of filtering out actionable mutations prior to molecular tumor board discussion (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Supplementary Methods; Somatic Variant Calling Strategy).</p>
          <p>Variants in the tumor were further characterized as homozygous, compound heterozygous, somatic, and “disruptive” (loss of function, namely, nonsense, frame-shift, or splice site). Spreadsheets with the various categories were presented to molecular pathologists for review. Quality statistics for WES and cWES are presented in Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S1. Targeted DNA sequencing was performed to an average 500X depth and analyzed as above. All DNA sequencing results were manually reviewed by molecular pathologists to prioritize variants for presentation at the multi-disciplinary tumor board and subsequent reporting of consensus variants. For mutation statistics, the list of “tumor-specific” variants obtained by comparison of vcfs was filtered for variants with at least 30X coverage in tumor and either a “quality score” ≥20 or a variant allelic fraction ≥25% in the tumor.</p>
          <sec id="Sec7">
            <title>Copy number variation</title>
            <p>CNV was identified using EXCAVATOR (v.2.2; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://sourceforge.net/projects/excavatortool">https://sourceforge.net/projects/excavatortool</ext-link>) software [<xref ref-type="bibr" rid="CR18">18</xref>]. For samples with greater than 95% of targeted nucleotides present at least 10X in the reference normal and at least 90% covered 30X in the corresponding tumor sample, EXCAVATOR was run with parameters chosen for moderate sensitivity (assuming a tumor percentage of 0.8) and cutoff for loss set to a log2 ratio of –0.2. In addition, all high quality heterozygous variants with variant allelic fractions (VAFs) in the range of 45–55% and 90–100% in the normal sample were output. The allelic ratio at these genomic coordinates in the tumor was also output for viewing on the integrated genomic viewer to allow identification of copy number neutral loss of heterozygosity (LOH) and to support the CNVs identified by EXCAVATOR. The laboratory detected all chromosome arm changes seen on karyotyping, losses of 26 Mb and greater seen on array CGH, and reproducibly identified all CNVs that involved at least ten exons at 40% tumor fraction (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Supplementary Methods).</p>
          </sec>
          <sec id="Sec8">
            <title>Transcriptome analysis</title>
            <p>For transcriptome analysis, fastq files from CASAVA were filtered for ribosomal RNA (rRNA) using SortMeRNA (v.1.7; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://bioinfo.lifl.fr/RNA/sortmerna/">http://bioinfo.lifl.fr/RNA/sortmerna/</ext-link>) and trimmed to remove poor-quality tails using TrimGalore (v.0.2.7; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/">http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/</ext-link>) with settings to exclude reads of quality score &lt;20 and read length &lt;20. Remaining reads were mapped to GRCh37 (hg19) using Tuxedo Suite [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] consisting of TopHat2 (v.2.0.8), BOWTIE2 (v.2.1.0), and CUFFLINKS (v.2.1.1). Non-uniquely mapped reads were excluded before estimation of fragments per kilobase per million reads (FPKMs) by CUFFLINKS. Mutation calling was performed using NextGene software. At least 50 million uniquely mapped reads were required with less than 5% DNA contamination. In addition, unmapped reads were analyzed using “FusionMap” (v.01/01/2015) to generate a list of fusions for review by molecular pathologists [<xref ref-type="bibr" rid="CR21">21</xref>]. To identify alterations in gene expression, the median FPKMs of 8000 housekeeping genes were used as reference [<xref ref-type="bibr" rid="CR22">22</xref>] and the relative expression of each gene was compared to 124 normal transcriptomes from various tissues (13 blood, 20 liver, 24 kidney, 17 lung, and 50 brain) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Supplementary Methods).</p>
          </sec>
        </sec>
        <sec id="Sec9">
          <title>Data interpretation and reporting</title>
          <p>Interpretation of clinical WES, RNA-seq, and CNV was conducted via a molecular tumor board with multi-disciplinary representation from pediatric oncology, pathology, cancer biology, molecular and clinical genetics, and bioinformatics. Following the tumor board, approximately 60 days after testing request, a tiered report was generated for clinical samples by pathology, sent to the referring physician and posted to the EMR according to the opt-in/opt-out selections of the patient consent. Only variants with good normal coverage (generally at least 30X) were detected on multiple independent fragments and were not excluded as likely benign were reported. For clinical testing, the report included variants that were justified by the literature as driver mutations (e.g. well characterized hot spot mutations); unambiguous loss of function mutations in tumor suppressor genes (i.e. nonsense or frame-shift mutations that resulted in loss of functional domains); mutations with published laboratory data documenting gain or loss of function in oncogenes and tumor suppressor genes, respectively; and previously reported fusions or fusions that were expected to have the same effect as previously reported fusions involving one of the partner genes. Certain exceptions for clinical testing were made. For example, if a variant was likely a strong driver (e.g. a known activating mutation of an oncogene) but had low coverage in the normal or appeared low-quality on review, the molecular pathologist still considered it but required independent confirmation by an orthogonal method prior to reporting.</p>
          <p>The final clinical cWES report included: known tumor type-specific actionable somatic mutations (Tier 1); somatic mutations in targetable pathways, actionable somatic mutations in other tumor types, somatic mutations in well-established cancer genes (Tier 2); other somatic mutations in cancer genes (Tier 3); and somatic VOUS (Tier 4). Reporting of germline findings included: known pathogenic secondary ACMG variants [<xref ref-type="bibr" rid="CR17">17</xref>]; secondary non-ACMG variants and selected VOUS in known cancer genes with commentary; and known variants that influence pharmacogenomics. Reports further included translocations, significantly overexpressed genes, and segmental CNV. A sample cWES report is presented in Additional file <xref rid="MOESM3" ref-type="media">3</xref>. Accession number for all genes and fusions referenced in the paper are reported in Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2. Datasets are available through the cBioPortal for Cancer Genomics (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cbioportal.org/">http://cbioportal.org</ext-link>) [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p>
          <p>Clinical utility, defined as the ability of a molecular test result to provide information related to the care of the patient and his/her family members to diagnose, monitor, prognosticate or predict disease progression, and inform treatment [<xref ref-type="bibr" rid="CR25">25</xref>], was used to evaluate the potential impact of findings from clinical sequencing. “Clinical impact” and “clinically impactful” are broad terms used throughout this paper to refer to any molecular test result that, when integrated with a patient’s history, symptoms, and other clinical findings, informed the medical team’s assessment or management of the patient. These clinically meaningful results were subcategorized into the following five categories to evaluate the potential clinical utility of tumor and germline alterations: (1) diagnostic; (2) prognostic; (3) identification of a therapeutic target; (4) other clinically impactful information, including pharmacogenomics or findings that resulted in a significant refinement of a therapeutic plan (e.g. choice of donor or withdrawal of recommendation for bone marrow transplantation); and (5) recommendations for health maintenance interventions or genetic counseling for the patient and other at-risk family members. Genetic alterations were considered targetable if: (1) an FDA approved drug or experimental drug was available that inhibited the target directly or inhibited its downstream signaling pathway; or (2) there was preclinical evidence to support efficient targeting of the aberrant function of the mutated gene and/or potential clinical benefit; and (3) there was some age-appropriate information on dosing. Targetable somatic mutations were further categorized using a five-tier system previously described by Wagle et al. [<xref ref-type="bibr" rid="CR26">26</xref>] and Harris et al. [<xref ref-type="bibr" rid="CR15">15</xref>]. This sub-tiering system uses the strength of preclinical and clinical data as evidence to support the potential clinical benefit of targeting an altered gene with a specific therapeutic agent.</p>
        </sec>
      </sec>
      <sec id="Sec10" sec-type="results">
        <title>Results</title>
        <sec id="Sec11">
          <title>Patients</title>
          <p>Demographic and clinical characteristics are presented in Table <xref rid="Tab1" ref-type="table">1</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>. Molecular characterization was performed on 120 samples (85, primary disease; 35, relapse/refractory disease) from 101 consecutive cases (mean age, 9.3 years; median age, 8.0 years; range, 2 weeks – 26 years). Patients aged over 18 years in this cohort were initially diagnosed with a pediatric disease under the age of 18 years. Testing included: full cWES (tumor, germline, and transcriptome; <italic toggle="yes">n</italic> = 63); cWES without transcriptome (<italic toggle="yes">n</italic> = 19); transcriptome only (<italic toggle="yes">n</italic> = 3); targeted tumor panel sequencing (<italic toggle="yes">n</italic> = 13); and constitutional WES (proband and parental blood) (<italic toggle="yes">n</italic> = 22). For constitutional WES, trios (proband and both parents) were performed in 18/22 cases, 3/22 cases only had one parent available for testing, and in one case only the proband was tested post-mortem. Eighty-four patients underwent single platform testing, while multiple sequencing platforms were used for 17 cases (36 samples). Cases were predominantly pediatric patients with solid tumors (64%) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>; Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S3). Sarcoma (<italic toggle="yes">n</italic> = 17) was the most common diagnostic sub-category followed by brain tumors (<italic toggle="yes">n</italic> = 16). Patients with lymphoid disease (<italic toggle="yes">n</italic> = 17) comprised the majority of hematological conditions (Fig. <xref rid="Fig1" ref-type="fig">1</xref>; Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S3).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Patient and sample characteristics (n = 101)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">n (%)</th></tr></thead><tbody><tr><td colspan="2" rowspan="1">Diagnostic category</td></tr><tr><td colspan="1" rowspan="1"> Solid tumors</td><td colspan="1" rowspan="1">65 (64)</td></tr><tr><td colspan="1" rowspan="1"> Hematologic conditions</td><td colspan="1" rowspan="1">36 (36)</td></tr><tr><td colspan="2" rowspan="1">Gender</td></tr><tr><td colspan="1" rowspan="1"> Male</td><td colspan="1" rowspan="1">60 (59)</td></tr><tr><td colspan="1" rowspan="1"> Female</td><td colspan="1" rowspan="1">41 (41)</td></tr><tr><td colspan="2" rowspan="1">Age (years)</td></tr><tr><td colspan="1" rowspan="1"> 0–5</td><td colspan="1" rowspan="1">35 (34)</td></tr><tr><td colspan="1" rowspan="1"> 6–12</td><td colspan="1" rowspan="1">30 (30)</td></tr><tr><td colspan="1" rowspan="1"> 13–17</td><td colspan="1" rowspan="1">20 (20)</td></tr><tr><td colspan="1" rowspan="1"> ≥18</td><td colspan="1" rowspan="1">16 (16)</td></tr><tr><td colspan="2" rowspan="1">Samples tested (n = 120)</td></tr><tr><td colspan="1" rowspan="1"> Primary disease</td><td colspan="1" rowspan="1">85 (71)</td></tr><tr><td colspan="1" rowspan="1"> Relapse/refractory</td><td colspan="1" rowspan="1">35 (29)</td></tr><tr><td colspan="2" rowspan="1">Platform (n = 120)</td></tr><tr><td colspan="1" rowspan="1"> Cancer WES with transcriptome</td><td colspan="1" rowspan="1">63 (53)</td></tr><tr><td colspan="1" rowspan="1"> Cancer WES</td><td colspan="1" rowspan="1">19 (16)</td></tr><tr><td colspan="1" rowspan="1"> Constitutional WES</td><td colspan="1" rowspan="1">22 (18)</td></tr><tr><td colspan="1" rowspan="1"> Transcriptome only</td><td colspan="1" rowspan="1">3 (2)</td></tr><tr><td colspan="1" rowspan="1"> Targeted panel (467 genes)</td><td colspan="1" rowspan="1">13 (11)</td></tr><tr><td colspan="2" rowspan="1">Normal tissue source (n = 104)</td></tr><tr><td colspan="1" rowspan="1"> Blood</td><td colspan="1" rowspan="1">78 (74)</td></tr><tr><td colspan="1" rowspan="1"> Buccal swab</td><td colspan="1" rowspan="1">23 (23)</td></tr><tr><td colspan="1" rowspan="1"> Unaffected tissue</td><td colspan="1" rowspan="1">3 (3)</td></tr></tbody></table><table-wrap-foot><p>
<italic toggle="yes">WES</italic> whole-exome sequencing</p></table-wrap-foot></table-wrap>
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>PIPseq overview. An overview of the PIPseq patients sequenced is presented on the <italic toggle="yes">left</italic> and a <italic toggle="yes">pie chart</italic> showing the distribution of diagnostic categories on the <italic toggle="yes">right</italic>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13073_2016_389_Fig1_HTML.jpg"/></fig>
</p>
        </sec>
        <sec id="Sec12">
          <title>Informed consent, cost, and reimbursement</title>
          <p>All patients were consented to genomic analysis either through a research consent or clinical WES consent. Of the 101 cases, 67 were consented using the clinical cWES consent. Only four (6%) opted out of learning secondary findings and 21 (31%) opted out of having secondary findings in their medical record. All patients consented to have leftover samples stored. Only a single patient (2%) opted out of future contact (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S4).</p>
          <p>As part of clinical implementation, we assessed the cost of cWES and RNA-seq and the reimbursement landscape. The total cost per case was calculated by summing the total variable cost (reagent cost, pathologist time) with the fixed cost per case (annual machine cost, annual maintenance, tech labor cost, informatics cost, space for NGS hardware, server time, NGS analysis lease, and data storage). The estimated cost of WES (tumor/normal) was $4459 and the cost of RNA-seq was $1764. These estimates do not include administrative overhead and billing for services.</p>
          <p>The time to receiving final reimbursement decisions from third-party payers ranged between 6 months to 1 year. To date, we have received a decision for 56 patients with 45/56 (80%) receiving partial reimbursement. The average reimbursement by carrier type was as follows: commercial, $2747 (range, $770–6917); managed government plans, $2918 (range, $750–4555); and $0 from government plans. Patients and their families were not charged for sequencing or analysis.</p>
        </sec>
        <sec id="Sec13">
          <title>Genomic alterations in pediatric solid tumors and hematologic disorders</title>
          <p>Over 150-fold and 500-fold average coverage was achieved by WES and targeted capture sequencing, respectively with &gt;98% of the coding sequences having at least tenfold coverage. The mean mutational load across patients was 216.9 variants (SD = 829.3, median = 69), with a higher mean mutational load in solid tumors compared to hematologic malignancies (Fig. <xref rid="Fig2" ref-type="fig">2</xref>; Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Figure S1). Genomic aberrations were reported in 92/101 patients (91%). After filtering, a total of 180 mutations (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S5) and 20 fusions were reported, 110 (including 10 fusions) from solid tumor samples (mean number of aberrations per sample, 2.91; median, 2.00; range, 1–6) and 90 (including 10 fusions) from hematologic samples (mean number of aberrations per sample, 5.2; median, 4.0; range, 1–12). The most commonly mutated gene was <italic toggle="yes">TP53</italic> (<italic toggle="yes">n</italic> = 9, 9%) in solid tumor samples and RAS pathway constituents (<italic toggle="yes">NRAS:</italic>
<italic toggle="yes">n</italic> = 5, 5%; <italic toggle="yes">KRAS:</italic>
<italic toggle="yes">n</italic> = 3, 3%) in hematologic samples (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). In addition, significant changes in the pattern of genetic alterations were noted on serial sequencing of samples from individual patients at different time points during their therapy, reflecting clonal evolution. Awareness of these changes is important for selecting an appropriate targeted therapy and assessing response to therapy.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Somatic mutation load by diagnostic category. <italic toggle="yes">Box plots</italic> comparing overall somatic mutation rates across solid tumors and hematologic conditions detected by NGS. The <italic toggle="yes">top</italic> and <italic toggle="yes">bottom</italic> ends of the <italic toggle="yes">boxes</italic> represent the 25th and 75th percentile values, respectively, and the segment in the <italic toggle="yes">middle</italic> is the median. The <italic toggle="yes">top</italic> and <italic toggle="yes">bottom</italic> extremes of the bars extend to the minimum and maximum values. The <italic toggle="yes">box plot</italic> depicts the total mutation load excluding four outliers (one solid tumor and three hematologic). See Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Figure S1 for inclusive dataset with outliers. The total mutational load (prior to filtering or orthogonal validation) for solid tumors was 4972 variants (mean, 84.3; SD, 43.9; median, 85; range, 15–214) and for hematologic conditions was 1478 variants (mean, 56.85; SD, 34.9; median, 47; range, 14–149)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13073_2016_389_Fig2_HTML.jpg"/></fig>
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Summary of informative results from the PIPseq program. A matrix representation of findings with biological significance from the sequencing results are presented. Data are derived from all 101 patients that underwent WES of tumor-normal sample pairs, exome sequencing of germline DNA, transcriptome analysis of tumor, CNV of tumor, and targeted panel sequencing of tumor only. Deleterious mutations were loss of function mutations and activating mutations refers to recurrent, previously reported activating mutations in oncogenes or variants with published in vitro evidence as being activating</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13073_2016_389_Fig3_HTML.jpg"/></fig>
</p>
        </sec>
        <sec id="Sec14">
          <title>Evaluating potential clinical utility and targetable alterations</title>
          <p>A genetic variant was considered targetable if: (1) an FDA-approved drug or experimental drug was available that inhibited the target directly or inhibited its downstream signaling pathway; or 2) there was preclinical evidence to support efficient targeting of the aberrant function of the mutated gene and/or potential clinical benefit; and 3) there was some age-appropriate information on dosing. Consistent with the published recommendations from the Association for Molecular Pathology [<xref ref-type="bibr" rid="CR25">25</xref>], we evaluated clinical utility based on “the ability of a test result to provide information to the patient, physician, and payer related to the care of the patient and his/her family members to diagnose, monitor, prognosticate, or predict disease progression, and to inform treatment and reproductive decisions.”</p>
        </sec>
        <sec id="Sec15">
          <title>Targetable somatic genomic alterations</title>
          <p>Overall, 38/101 patients (38%) had at least one potentially targetable genomic alteration (Table <xref rid="Tab2" ref-type="table">2</xref>). Specifically, 21/65 patients (32%) with solid tumors and 17/36 (47%) patients with hematologic conditions carried targetable alterations. Matched therapy based on genomic findings was received in 6/38 patients (16%).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Sub-classification of potentially targetable somatic mutations for treatment planning</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">PIP ID</th><th colspan="1" rowspan="1">Diagnosis</th><th colspan="1" rowspan="1">Target alteration</th><th colspan="1" rowspan="1">Mutation (change)</th><th colspan="1" rowspan="1">Potential target therapy</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Tier 1 (Data demonstrating benefit- same tumor type, same gene)</td></tr><tr><td colspan="1" rowspan="1"> 14-85546</td><td colspan="1" rowspan="1">CML</td><td colspan="1" rowspan="1">
<italic toggle="yes">BCR-ABL1</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">TKI</td></tr><tr><td colspan="1" rowspan="1"> 13-45348<sup>a</sup>
</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">IDH1</italic>
</td><td colspan="1" rowspan="1">c.394C &gt; T (p.R132C)</td><td colspan="1" rowspan="1">IDH Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-24794<sup>a</sup>
</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">c-KIT; TET2; FLT3</italic>
</td><td colspan="1" rowspan="1">c.2446G &gt; C (p.D816H); c.3663delT (p.C1221Wfs); c.2505 T &gt; G (p.D835E)</td><td colspan="1" rowspan="1">TKI; Hypomethylating agent; TKI</td></tr><tr><td colspan="1" rowspan="1"> 14-53198</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">TET2</italic>
</td><td colspan="1" rowspan="1">c.1156G &gt; T (p.V386L)</td><td colspan="1" rowspan="1">Hypomethylating agent</td></tr><tr><td colspan="1" rowspan="1"> 13-77086</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">c-KIT</italic>
</td><td colspan="1" rowspan="1">c.1965 T &gt; G (p.Asn655Lys)</td><td colspan="1" rowspan="1">TKI<sup>b</sup>
</td></tr><tr><td colspan="5" rowspan="1">Tier 2 (Data demonstrating benefit- different tumor type, same gene)</td></tr><tr><td colspan="1" rowspan="1"> 15-18928</td><td colspan="1" rowspan="1">Hepatic rhabdoid tumor</td><td colspan="1" rowspan="1">
<italic toggle="yes">SMARCA4</italic>
</td><td colspan="1" rowspan="1">c.3574C &gt; T (p.R1192C)</td><td colspan="1" rowspan="1">EZH2 Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-13487</td><td colspan="1" rowspan="1">Osteosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">TSC1</italic>
</td><td colspan="1" rowspan="1">c.2503-1G &gt; C (p.?)</td><td colspan="1" rowspan="1">mTOR Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-47205</td><td colspan="1" rowspan="1">Nephroblastomatosis</td><td colspan="1" rowspan="1">
<italic toggle="yes">PIK3CA</italic>
</td><td colspan="1" rowspan="1">c.1035 T &gt; A (p.N345K)</td><td colspan="1" rowspan="1">PI3K/AKT/mTOR Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-40141</td><td colspan="1" rowspan="1">Pleomorphic xanthoastrocytoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">TMEM106B-BRAF</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="5" rowspan="1">Tier 3 (Published, presented, in press pre-clinical data demonstrating benefit- same tumor type, same gene)</td></tr><tr><td colspan="1" rowspan="1"> 15-64793</td><td colspan="1" rowspan="1">ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">FOXP1-ABL1</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">TKI<sup>b</sup>
</td></tr><tr><td colspan="1" rowspan="1"> 15-26188</td><td colspan="1" rowspan="1">ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">NUP214-ABL1</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">TKI<sup>b</sup>
</td></tr><tr><td colspan="1" rowspan="1"> 15-79700</td><td colspan="1" rowspan="1">ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">NRAS</italic>
</td><td colspan="1" rowspan="1">c.183A &gt; T (p.Q61H)</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-20062</td><td colspan="1" rowspan="1">ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">KRAS</italic>
</td><td colspan="1" rowspan="1">c.183A &gt; T (p.Q61H)</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-24794<sup>a</sup>
</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">NRAS</italic>
</td><td colspan="1" rowspan="1">c.183A &gt; C (p.Q61H)</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-29224</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">JAK3</italic>
</td><td colspan="1" rowspan="1">c.1718C &gt; T (p.A573V)</td><td colspan="1" rowspan="1">JAK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 13-45348<sup>a</sup>
</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">NRAS</italic>
</td><td colspan="1" rowspan="1">c.38G &gt; C (p.G13A)</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 13-95124</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">NRAS; MLL-AFF1 (KMT2A-AFF1)</italic>
</td><td colspan="1" rowspan="1">c.182A &gt; G (p.Q61R); Fusion</td><td colspan="1" rowspan="1">MEK Inhibitor; DOT1L Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-45760</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">NRAS</italic>
</td><td colspan="1" rowspan="1">c.38G &gt; A (p.G13D)</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 13-50662</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">PTPN11</italic>
</td><td colspan="1" rowspan="1">c.1508G &gt; T (p.G503V)</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-15491</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">NUP98-NSD1</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">DOT1L Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-27243</td><td colspan="1" rowspan="1">Neuroblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">NRAS</italic>
</td><td colspan="1" rowspan="1">c.181C &gt; A (p.Q61K)</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-70449</td><td colspan="1" rowspan="1">Rhabdomyosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">NRAS</italic>
</td><td colspan="1" rowspan="1">c.181C &gt; A (p.Q61K)</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-42817</td><td colspan="1" rowspan="1">Neuroblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">KRAS</italic>
</td><td colspan="1" rowspan="1">c.34G &gt; T (p.G12C)</td><td colspan="1" rowspan="1">MEK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-11925<sup>a</sup>
</td><td colspan="1" rowspan="1">Osteosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">MYC</italic>
</td><td colspan="1" rowspan="1">Overexpression</td><td colspan="1" rowspan="1">BET Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 16-74654</td><td colspan="1" rowspan="1">Rhabdomyosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">FGFR4</italic>
</td><td colspan="1" rowspan="1">c.1582G &gt; T (p.G528C); c.1648G &gt; C (p.V550L)</td><td colspan="1" rowspan="1">FGFR4 Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-23518</td><td colspan="1" rowspan="1">Rhabdomyosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">FGFR4</italic>
</td><td colspan="1" rowspan="1">c.1648G &gt; C (p.V550L); c.1949G &gt; T (p.R650L); Overexpression</td><td colspan="1" rowspan="1">FGFR4 Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-37237</td><td colspan="1" rowspan="1">Glioblastoma multiforme</td><td colspan="1" rowspan="1">
<italic toggle="yes">Gain 12q.14.1 involving CDK2</italic>
</td><td colspan="1" rowspan="1">Copy number</td><td colspan="1" rowspan="1">CDK4/6 Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-44470</td><td colspan="1" rowspan="1">Medulloblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">PTCH1, SUFU, ZIC3</italic>
</td><td colspan="1" rowspan="1">Overexpression</td><td colspan="1" rowspan="1">SMO Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-10838</td><td colspan="1" rowspan="1">Glioma</td><td colspan="1" rowspan="1">
<italic toggle="yes">H3F3A; FGFR1</italic>
</td><td colspan="1" rowspan="1">c.83A &gt; T (p.K28M); c.1731C &gt; A (p.N577K)</td><td colspan="1" rowspan="1">HDAC Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-27992</td><td colspan="1" rowspan="1">Hepatic rhabdoid tumor</td><td colspan="1" rowspan="1">
<italic toggle="yes">Homozygous deletion of chr 22q11.23 with homozygous deletion of SMARCB1; Loss of expression of SMARCB1</italic>
</td><td colspan="1" rowspan="1">Copy number; Loss of expression with biallelic deletion</td><td colspan="1" rowspan="1">EZH2 Inhibitor</td></tr><tr><td colspan="5" rowspan="1">Tier 4 (Published, presented, in press pre-clinical data demonstrating benefit- different tumor type, same gene)</td></tr><tr><td colspan="1" rowspan="1"> 15-36388</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">MLL3 (KMT2C)</italic>
</td><td colspan="1" rowspan="1">c.2110G &gt; T (p.E704X)</td><td colspan="1" rowspan="1">BET Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 13-72282</td><td colspan="1" rowspan="1">T-ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">KRAS; JAK1; STAT5B</italic>
</td><td colspan="1" rowspan="1">c.40G &gt; A (p.V14I); c.3076A &gt; G (p.K1026E); c.2110A &gt; C (p.I704L)</td><td colspan="1" rowspan="1">MEK Inhibitor; JAK Inhibitor; BCL2/BCLX-L Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-66870</td><td colspan="1" rowspan="1">Adrenocortical carcinoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">ALK</italic>
</td><td colspan="1" rowspan="1">c.3436C &gt; A (p.Q1146K)</td><td colspan="1" rowspan="1">ALK Inhibitor<sup>b</sup>
</td></tr><tr><td colspan="5" rowspan="1">Tier 5 (Anything else the molecular tumor board thought was sufficient to qualify for treatment planning)</td></tr><tr><td colspan="1" rowspan="1"> 15-16072</td><td colspan="1" rowspan="1">ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">SMARCC2-PDGFRB</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">TKI</td></tr><tr><td colspan="1" rowspan="1"> 14-75899</td><td colspan="1" rowspan="1">Neuroblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">CDK4, MDM2</italic>
</td><td colspan="1" rowspan="1">Overexpression</td><td colspan="1" rowspan="1">NEPENTHE trial [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02780128">NCT02780128</ext-link>]</td></tr><tr><td colspan="1" rowspan="1"> 15-11925<sup>a</sup>
</td><td colspan="1" rowspan="1">Osteosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">MCL1, CCNE1</italic>
</td><td colspan="1" rowspan="1">Overexpression</td><td colspan="1" rowspan="1">CDK4/6 Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-35162</td><td colspan="1" rowspan="1">Osteosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">CUL4A</italic>
</td><td colspan="1" rowspan="1">Overexpression</td><td colspan="1" rowspan="1">NAE Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-71727</td><td colspan="1" rowspan="1">Osteosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">RAD51C</italic>
</td><td colspan="1" rowspan="1">c.24 T &gt; G (p.F8L)</td><td colspan="1" rowspan="1">PARP Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 15-83826</td><td colspan="1" rowspan="1">Osteosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">PDGFRA, KDR (VEGFR2)</italic>
</td><td colspan="1" rowspan="1">Overexpression</td><td colspan="1" rowspan="1">MTKI<sup>b</sup>
</td></tr><tr><td colspan="1" rowspan="1"> 13-21968</td><td colspan="1" rowspan="1">Congenital fibrosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">EML4-NTRK3</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">ALK Inhibitor</td></tr><tr><td colspan="1" rowspan="1"> 14-84044</td><td colspan="1" rowspan="1">Inflammatory myofibroblastic tumor</td><td colspan="1" rowspan="1">
<italic toggle="yes">VCAN-IL23R</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">JAK Inhibitor<sup>b</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Same patient</p><p>
<sup>b</sup>Targeted therapy received</p><p>
<italic toggle="yes">ALL</italic> acute lymphoblastic leukemia, <italic toggle="yes">AML</italic> acute myeloid leukemia, <italic toggle="yes">CML</italic> chronic myeloid leukemia</p></table-wrap-foot></table-wrap>
</p>
          <p>Examples of targetable alterations include the identification of a <italic toggle="yes">cKIT</italic> (p.Asn655Lys) [<xref ref-type="bibr" rid="CR27">27</xref>] mutation in a 7-year-old boy with acute myeloid leukemia (AML), who was subsequently treated with palliative imatinib and achieved a near-complete clearing of peripheral blood leukemic blasts with a sustained response for 9 months. The RNA expression data also led us to identify a <italic toggle="yes">BCR-ABL1-</italic>like [<xref ref-type="bibr" rid="CR28">28</xref>] expression pattern in a 9-year-old girl with relapsed, refractory B-cell acute lymphoblastic leukemia (ALL). Subsequent analysis identified a <italic toggle="yes">NUP214-ABL1</italic> [<xref ref-type="bibr" rid="CR29">29</xref>] fusion by real-time polymerase chain reaction (RT-PCR) and the addition of dasatinib to the third-line induction regimen resulted in a deep remission allowing for a curative bone marrow transplant. These results demonstrate the utility of comprehensive genomic characterization to identify clinically actionable alterations in pediatric oncology patients.</p>
        </sec>
        <sec id="Sec16">
          <title>Clinical impact of non-targetable somatic mutations</title>
          <p>While many studies have focused on actionable alterations, the potential clinical impact of non-targetable alterations was also evaluated. Genomic alterations identified by sequencing helped to confer a molecular diagnosis in 23 patients and identified prognostic, pharmacogenomic, and other significant health maintenance recommendations in 32 patients (Table <xref rid="Tab3" ref-type="table">3</xref>). Although these findings do not meet the definition of “actionability,” the clinical impact of such findings can be quite profound. For example, the identification of a <italic toggle="yes">STAT5B</italic> mutation [<xref ref-type="bibr" rid="CR30">30</xref>] in a 5-year-old girl erroneously diagnosed with T-cell ALL helped to establish a diagnosis of gamma-delta T-cell lymphoma. Also, identification of a <italic toggle="yes">PTPN11</italic> mutation in a 4-year-old boy contributed to a change in his diagnosis from de novo AML to juvenile myelomonocytic leukemia (JMML) which evolved into AML [<xref ref-type="bibr" rid="CR31">31</xref>].<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Clinical utility beyond targetable somatic mutations</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">PIP ID</th><th colspan="1" rowspan="1">Diagnosis</th><th colspan="1" rowspan="1">Alteration</th><th colspan="1" rowspan="1">Mutation (change)</th><th colspan="1" rowspan="1">Clinical utility</th><th colspan="1" rowspan="1">Implication</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Sequence mutations</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"> 15-63375</td><td colspan="1" rowspan="1">AML changed to JMML</td><td colspan="1" rowspan="1">
<italic toggle="yes">PTPN11; SETB1</italic>
</td><td colspan="1" rowspan="1">c.181G &gt; T (p.D61Y); c.2602G &gt; A (p.D868N)</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]</td><td colspan="1" rowspan="1">JMML</td></tr><tr><td colspan="1" rowspan="1"> 13-72282<sup>a</sup>
</td><td colspan="1" rowspan="1">T-ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">STAT5B</italic>
</td><td colspan="1" rowspan="1">c.2110A &gt; C (p.I704L)</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]</td><td colspan="1" rowspan="1">Gamma-delta T-cell lymphoma</td></tr><tr><td colspan="1" rowspan="1"> 15-26188</td><td colspan="1" rowspan="1">ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">NT5C2</italic>
</td><td colspan="1" rowspan="1">c.1219G &gt; T (p.D407Y)</td><td colspan="1" rowspan="1">Pharmacogenomic [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]</td><td colspan="1" rowspan="1">Affects therapy</td></tr><tr><td colspan="1" rowspan="1"> 13-45348</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">IDH1</italic>
</td><td colspan="1" rowspan="1">c.394C &gt; T (p.R132C)</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]</td><td colspan="1" rowspan="1">Maffucci syndrome</td></tr><tr><td colspan="1" rowspan="1"> 14-53198</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">CEBPA</italic>
</td><td colspan="1" rowspan="1">c.939_940insAAG (p.K313_V314insK); c.326_327insC (p.P109fs)</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td colspan="1" rowspan="1">Improved prognosis</td></tr><tr><td colspan="1" rowspan="1"> 15-10838</td><td colspan="1" rowspan="1">Glioma</td><td colspan="1" rowspan="1">
<italic toggle="yes">H3F3A</italic>
</td><td colspan="1" rowspan="1">c.83A &gt; T (p.K28M)</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td colspan="1" rowspan="1">Poor prognosis</td></tr><tr><td colspan="1" rowspan="1"> 14-37237</td><td colspan="1" rowspan="1">Glioblastoma multiforme</td><td colspan="1" rowspan="1">
<italic toggle="yes">H3F3A</italic>
</td><td colspan="1" rowspan="1">c.83A &gt; T (p.K28M)</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]</td><td colspan="1" rowspan="1">GBM subgroup, K27</td></tr><tr><td colspan="1" rowspan="1"> 14-35585</td><td colspan="1" rowspan="1">Renal cell carcinoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">VHL</italic>
</td><td colspan="1" rowspan="1">c.497 T &gt; G (p.V166G)</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td colspan="1" rowspan="1">Von Hippel Lindau</td></tr><tr><td colspan="1" rowspan="1"> 14-47205</td><td colspan="1" rowspan="1">Nephroblastomatosis</td><td colspan="1" rowspan="1">
<italic toggle="yes">PIK3CA</italic>
</td><td colspan="1" rowspan="1">c.1035 T &gt; A (p.N345K)</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td colspan="1" rowspan="1">Nephroblastomatosis</td></tr><tr><td colspan="1" rowspan="1"> 14-78154<sup>a</sup>
</td><td colspan="1" rowspan="1">Medulloblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">KDM6A</italic>
</td><td colspan="1" rowspan="1">c.2989_2990dupAT (p.M997fs)</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td colspan="1" rowspan="1">Risk stratification, group 4</td></tr><tr><td colspan="1" rowspan="1"> 14-75899</td><td colspan="1" rowspan="1">Neuroblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">ATRX</italic>
</td><td colspan="1" rowspan="1">c.5239delA (p.T1747fs)</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td colspan="1" rowspan="1">Poor prognosis</td></tr><tr><td colspan="1" rowspan="1"> 14-10141</td><td colspan="1" rowspan="1">Pleuropulmonaryblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">DICER1</italic>
</td><td colspan="1" rowspan="1">c.5438A &gt; G (p.E1813G)</td><td colspan="1" rowspan="1">Health Maintenance [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td colspan="1" rowspan="1">DICER syndrome</td></tr><tr><td colspan="6" rowspan="1">Transcriptome analysis and CNV</td></tr><tr><td colspan="1" rowspan="1"> 14-24794</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">CBFB-MYH11</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td colspan="1" rowspan="1">Low-risk stratification</td></tr><tr><td colspan="1" rowspan="1"> 15-64793</td><td colspan="1" rowspan="1">B-ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">FOXP1-ABL1</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td colspan="1" rowspan="1">High-risk stratification</td></tr><tr><td colspan="1" rowspan="1"> 15-84578</td><td colspan="1" rowspan="1">AMKL</td><td colspan="1" rowspan="1">
<italic toggle="yes">CBFA2T3-GLIS2</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR61">61</xref>]; Prognostic [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td colspan="1" rowspan="1">AMKL; Poor prognosis</td></tr><tr><td colspan="1" rowspan="1"> 14-85546</td><td colspan="1" rowspan="1">CML</td><td colspan="1" rowspan="1">
<italic toggle="yes">BCR-ABL1</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td colspan="1" rowspan="1">CML</td></tr><tr><td colspan="1" rowspan="1"> 13-72282<sup>a</sup>
</td><td colspan="1" rowspan="1">T-ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">Isochromosome 7q</italic>
</td><td colspan="1" rowspan="1">Copy number change</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td colspan="1" rowspan="1">Gamma-delta T-cell lymphoma</td></tr><tr><td colspan="1" rowspan="1"> 15-46387</td><td colspan="1" rowspan="1">Rhabdomyosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">PAX7-FOXO1</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]; Prognostic [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td colspan="1" rowspan="1">Rhabdomyosarcoma; High-risk group</td></tr><tr><td colspan="1" rowspan="1"> 13-81192</td><td colspan="1" rowspan="1">Alveolar soft part sarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">ASPSCR1-TFE3</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td colspan="1" rowspan="1">Alveolar soft part sarcoma</td></tr><tr><td colspan="1" rowspan="1"> 13-65217</td><td colspan="1" rowspan="1">Ewing sarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">EWSR1-FLI1</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td colspan="1" rowspan="1">Ewing sarcoma</td></tr><tr><td colspan="1" rowspan="1"> 15-47087</td><td colspan="1" rowspan="1">Ewing sarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">EWSR1-FLI1; Low expression of PAX8, FHIT, CASP10, CHD2, with high expression of CHD11, FUS, and MTA1</italic>
</td><td colspan="1" rowspan="1">Fusion; Expression pattern</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR66">66</xref>]; Prognostic [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td colspan="1" rowspan="1">Ewing sarcoma; Poor prognosis</td></tr><tr><td colspan="1" rowspan="1"> 13-21968</td><td colspan="1" rowspan="1">Undifferentiated sarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">EML4-NTRK3</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td colspan="1" rowspan="1">Infantile fibrosarcoma</td></tr><tr><td colspan="1" rowspan="1"> 16-88073</td><td colspan="1" rowspan="1">Ependymoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">C11orf95-RELA; Alternating gains and losses on chr 11 and 22, consistent with a “chromothripsis-like” pattern</italic>
</td><td colspan="1" rowspan="1">Fusion; Copy number change</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR67">67</xref>]; Diagnostic [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td colspan="1" rowspan="1">Poor prognosis; RELA-type supratentorial ependymoma</td></tr><tr><td colspan="1" rowspan="1"> 14-27243</td><td colspan="1" rowspan="1">Neuroblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">MYCN amplified, deletion at 1p and 11q, gain 17q; MYCN over expressed</italic>
</td><td colspan="1" rowspan="1">Copy number change; Overexpression</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]</td><td colspan="1" rowspan="1">Risk-based therapy</td></tr><tr><td colspan="1" rowspan="1"> 14-42817</td><td colspan="1" rowspan="1">Neuroblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">MYCN non-amplified, no LOH at 1p11q; MYCN not over expressed</italic>
</td><td colspan="1" rowspan="1">Copy number change; No overexpression</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]</td><td colspan="1" rowspan="1">Risk-based therapy</td></tr><tr><td colspan="1" rowspan="1"> 15-39486</td><td colspan="1" rowspan="1">Neuroblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">MYCN non-amplified, no LOH at 1p11q; MYCN not over expressed</italic>
</td><td colspan="1" rowspan="1">Copy number change; No overexpression</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]</td><td colspan="1" rowspan="1">Risk-based therapy</td></tr><tr><td colspan="1" rowspan="1"> 14-44070</td><td colspan="1" rowspan="1">Neuroblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">MYCN amplified, loss of 1p, gain of 1q and 17q; MYCN over expressed</italic>
</td><td colspan="1" rowspan="1">Copy number change; Overexpression</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]</td><td colspan="1" rowspan="1">Risk-based therapy</td></tr><tr><td colspan="1" rowspan="1"> 15-88980</td><td colspan="1" rowspan="1">Hepatoblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">Amplification of 11q13.2 including CCND1; Over expression of CCND1</italic>
</td><td colspan="1" rowspan="1">Copy number change; Overexpression</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td colspan="1" rowspan="1">Good prognosis</td></tr><tr><td colspan="1" rowspan="1"> 15-49177</td><td colspan="1" rowspan="1">Medulloblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">IMPG2, GABRA5, LAPTM4B, MAB21L2, NPR3, MFAP4, NRL, ZFPM2, TSHZ3, IGF2BP3, GALNT14, GPR98; Loss of 10q22.2-10qter involving PTEN and SUFU, loss of 17p, gain of 17q</italic>
</td><td colspan="1" rowspan="1">Overexpression; Copy number change</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td colspan="1" rowspan="1">Risk stratification, subgroup 3/4</td></tr><tr><td colspan="1" rowspan="1"> 15-70532</td><td colspan="1" rowspan="1">Ependymoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">Gain of 1q, loss of 6q</italic>
</td><td colspan="1" rowspan="1">Copy number change</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR73">73</xref>–<xref ref-type="bibr" rid="CR75">75</xref>]</td><td colspan="1" rowspan="1">Poor prognosis</td></tr><tr><td colspan="1" rowspan="1"> 14-78154<sup>a</sup>
</td><td colspan="1" rowspan="1">Medulloblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">KCNA1, RBM24, KLHL13, EN2, SNCAIP, PDE1C, GRM8, KCNIP4, EXPH5, UNC5D, NID2, ST18, GPR12, SH3GL3; i17q</italic>
</td><td colspan="1" rowspan="1">Overexpression; Copy number change</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td colspan="1" rowspan="1">Risk stratification, subgroup 4</td></tr><tr><td colspan="1" rowspan="1"> 15-40141</td><td colspan="1" rowspan="1">Pleomorphic xanthoastrocytoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">Gain of chromosome 7, LOH at 9p</italic>
</td><td colspan="1" rowspan="1">Copy number change</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR76">76</xref>]</td><td colspan="1" rowspan="1">Pleomorphic xanthoastrocytoma</td></tr><tr><td colspan="1" rowspan="1"> 15-97336</td><td colspan="1" rowspan="1">Small round blue cell tumor</td><td colspan="1" rowspan="1">
<italic toggle="yes">EWSR1-WT1</italic>
</td><td colspan="1" rowspan="1">Fusion</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR77">77</xref>]</td><td colspan="1" rowspan="1">DSRCT</td></tr><tr><td colspan="1" rowspan="1"> 15-34296</td><td colspan="1" rowspan="1">Ependymoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">TNC, CALB1, PLAG1, ALDH1L1, RELN</italic>
</td><td colspan="1" rowspan="1">Overexpression</td><td colspan="1" rowspan="1">Prognostic [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td colspan="1" rowspan="1">Risk stratification, group A, poor prognosis</td></tr><tr><td colspan="1" rowspan="1"> 15-80972</td><td colspan="1" rowspan="1">ATRT</td><td colspan="1" rowspan="1">
<italic toggle="yes">LOH at 22q11.21qter, including SMARCB1; ASCL1</italic>
</td><td colspan="1" rowspan="1">Copy number change; Overexpression</td><td colspan="1" rowspan="1">Diagnostic [<xref ref-type="bibr" rid="CR78">78</xref>]; Prognostic [<xref ref-type="bibr" rid="CR79">79</xref>]</td><td colspan="1" rowspan="1">ATRT; Improved prognosis</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Same patient</p><p>
<italic toggle="yes">ALL</italic> acute lymphoblastic leukemia, <italic toggle="yes">AMKL</italic> acute megakaryoblastic leukemia, <italic toggle="yes">AML</italic> acute myeloid leukemia, <italic toggle="yes">ATRT</italic> atypical teratoid rhaboid tumor, <italic toggle="yes">CML</italic> chronic myeloid leukemia, <italic toggle="yes">CNV</italic> copy number variation, <italic toggle="yes">JMML</italic> juvenile myelomonocytic leukemia</p></table-wrap-foot></table-wrap>
</p>
          <p>The identification of resistance alleles likewise is not considered actionable, but may carry significant clinical implications. For example, in the 9-year-old girl with the relapsed <italic toggle="yes">NUP214-ABL1</italic> B-ALL, the finding of a <italic toggle="yes">NT5C2</italic> mutation associated with resistance to nucleoside analog therapies [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] had clear implications for her salvage therapy. In aggregate, sequencing results were clinically informative for diagnostic, prognostic, or pharmacogenomic purposes in 38 patients (38%).</p>
        </sec>
        <sec id="Sec17">
          <title>Clinical impact of transcriptome and CNV analysis beyond target identification</title>
          <p>Clinical impact by RNA-seq and CNV analysis was demonstrated in 23/33 patients (70%) (Table <xref rid="Tab3" ref-type="table">3</xref>). Gene fusions confirming diagnosis were found in five patients: <italic toggle="yes">BCR-ABL1</italic> (chronic myeloid leukemia), <italic toggle="yes">ASPSCR1-TFE3</italic> (alveolar soft part sarcoma), <italic toggle="yes">EWSR1-FLI1</italic> in two patients (Ewing sarcoma), and <italic toggle="yes">EWSR1-WTI</italic> (desmoplastic small round cell tumor). A novel <italic toggle="yes">EML4-NTRK3</italic> fusion found in a 2-year-old boy supported a change in diagnosis from undifferentiated sarcoma to infantile fibrosarcoma [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. In one patient, a <italic toggle="yes">CBFA2T3-GLIS2</italic> [<xref ref-type="bibr" rid="CR35">35</xref>] fusion confirmed the diagnosis of acute megakaryoblastic leukemia (AMKL), was associated with poor prognosis, and supported the recommendation for a bone marrow transplant. A <italic toggle="yes">PAX7-FOXO1</italic> fusion was diagnostic and prognostic in a toddler with histologically defined solid alveolar rhabdomyosarcoma, but in whom FISH analysis using the FOXO1A (FKHR; 13q14.1) break-apart probe was repeatedly negative.</p>
          <p>CNV was inferred from the WES data and relative gene expression was determined by reference to an averaged gene expression model. Segmental and gene expression changes having prognostic implications were identified in 11 patients with a variety of diagnoses. Four patients diagnosed with neuroblastoma could be stratified based on RNA-seq and CNV: one high-risk patient with MYCN amplification, LOH at 1p and 11q, gain of 17q, and MYCN overexpression; one high-risk patient with MYCN amplification, LOH at 1p, gain of 17q, and MYCN overexpression; one high-risk patient without MYCN amplification or LOH at 1p and 11q, and no evidence of MYCN overexpression; and one intermediate-risk patient without MYCN amplification or LOH at 1p and 11q and no evidence of MYCN overexpression. Medulloblastoma subgrouping was supported by overexpression and CNV in two patients. Poor prognostic features were found in two other patients: low expression of <italic toggle="yes">PAX8</italic>, <italic toggle="yes">FHIT</italic>, <italic toggle="yes">CASP10</italic>, <italic toggle="yes">CHD2</italic>, with high expression of <italic toggle="yes">CHD11</italic>, <italic toggle="yes">FUS</italic>, and <italic toggle="yes">MTA1</italic> in a patient with Ewing sarcoma [<xref ref-type="bibr" rid="CR36">36</xref>], and gain of 1q and loss of 6q and overexpression of <italic toggle="yes">TNC</italic>, <italic toggle="yes">CALB1</italic>, <italic toggle="yes">PLAG1</italic>, <italic toggle="yes">ALDH1L1</italic>, and <italic toggle="yes">RELN</italic> in a patient with ependymoma [<xref ref-type="bibr" rid="CR37">37</xref>]. Overexpression of <italic toggle="yes">CCND1</italic> in a patient with hepatoblastoma was considered a good prognostic indicator. One patient with AML with a <italic toggle="yes">CBFB-MYH11</italic> fusion could be assigned to risk-based therapy and the diagnosis of gamma-delta T-cell lymphoma [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] was also corroborated by CNV with isochromosome 7q.</p>
        </sec>
        <sec id="Sec18">
          <title>Clinically impactful germline alterations</title>
          <p>A total of 90 patients had germline tissue sequenced. Cancer WES included germline analysis in 68/90 patients. Tumor sequencing plus constitutional WES was performed in eight patients and 14 patients had only germline tissue sequenced for a variety of indications including clinical suspicion of cancer predisposition or of an underlying immunologic defect responsible for the development of lymphoma or hemophagocytic lymphohistiocytosis (HLH).</p>
          <p>Clinically impactful germline alterations (Table <xref rid="Tab4" ref-type="table">4</xref>) were found in 18/90 patients (20%): 11/57 patients with solid tumors (19%) and 7/33 patients with hematologic conditions (21%). In the solid tumor category, two alterations in <italic toggle="yes">APC</italic> were diagnostic: one in a patient with hepatoblastoma and a family history consistent with familial adenomatous polyposis (FAP; p.R1114) and one associated with newly appreciated Gardner’s syndrome (p.E1554fs) in a 14-year-old boy with pilomatricomas and epidermoid cysts prior to his carcinoma diagnosis. Two variants in <italic toggle="yes">ATM</italic> (p.R189K, p.K2756*) were found in a 16-year-old boy with medulloblastoma inferring an increased risk for developing other cancers. All were referred for genetic counseling and consideration for future cancer screening in the patient and family.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Clinically impactful germline mutations</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">PIP ID</th><th colspan="1" rowspan="1">Diagnosis</th><th colspan="1" rowspan="1">Alteration</th><th colspan="1" rowspan="1">Mutation</th><th colspan="1" rowspan="1">Change</th><th colspan="1" rowspan="1">Mutation type</th><th colspan="1" rowspan="1">Clinical utility</th><th colspan="1" rowspan="1">Implication</th><th colspan="1" rowspan="1">Previously known or suspected</th></tr></thead><tbody><tr><td colspan="9" rowspan="1">Hematologic conditions</td></tr><tr><td colspan="1" rowspan="1"> 14-19751</td><td colspan="1" rowspan="1">HLH</td><td colspan="1" rowspan="1">
<italic toggle="yes">MLL2</italic>
</td><td colspan="1" rowspan="1">c.11640_11640delG; c.15631G &gt; A</td><td colspan="1" rowspan="1">p.M3881Cfs*9 <italic toggle="yes">(de novo)</italic>; p.E5211K</td><td colspan="1" rowspan="1">Compound heterozygous, frameshift</td><td colspan="1" rowspan="1">Diagnostic</td><td colspan="1" rowspan="1">Kabuki syndrome; Transplantation withheld</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 15-90485</td><td colspan="1" rowspan="1">HLH</td><td colspan="1" rowspan="1">
<italic toggle="yes">C1QA</italic>
</td><td colspan="1" rowspan="1">c.622C &gt; T</td><td colspan="1" rowspan="1">p.Gln208Ter</td><td colspan="1" rowspan="1">Homozygous, nonsense</td><td colspan="1" rowspan="1">Diagnostic</td><td colspan="1" rowspan="1">C1Q deficiency</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 15-33031</td><td colspan="1" rowspan="1">MDS</td><td colspan="1" rowspan="1">
<italic toggle="yes">GATA2 (de novo)</italic>
</td><td colspan="1" rowspan="1">c.16delG</td><td colspan="1" rowspan="1">p.(E6fs)</td><td colspan="1" rowspan="1">Heterozygous, frameshift</td><td colspan="1" rowspan="1">Supports transplant recommendation; Genetic counseling for family</td><td colspan="1" rowspan="1">Increased risk for developing AML and MDS</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 14-92247</td><td colspan="1" rowspan="1">ALL</td><td colspan="1" rowspan="1">
<italic toggle="yes">PMS2</italic>
</td><td colspan="1" rowspan="1">c.1376C &gt; G</td><td colspan="1" rowspan="1">p.S459X</td><td colspan="1" rowspan="1">Homozygous, missense</td><td colspan="1" rowspan="1">Diagnostic; Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Constitutional mismatch repair deficiency syndrome; Lynch syndrome (parents)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 15-46877</td><td colspan="1" rowspan="1">HLH</td><td colspan="1" rowspan="1">
<italic toggle="yes">XIAP</italic>
</td><td colspan="1" rowspan="1">c.1328G &gt; C</td><td colspan="1" rowspan="1">p.R443P</td><td colspan="1" rowspan="1">Missense</td><td colspan="1" rowspan="1">Diagnostic</td><td colspan="1" rowspan="1">X-linked lymphoproliferative syndrome 2 (XLP2); Transplantation recommended</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 14-19750</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">RUNX1</italic>
</td><td colspan="1" rowspan="1">c.806-2A &gt; G</td><td colspan="1" rowspan="1">r.Spl?</td><td colspan="1" rowspan="1">Heterozygous splice site</td><td colspan="1" rowspan="1">Diagnostic</td><td colspan="1" rowspan="1">Familial platelet disorder; Transplantation donor changed from sibling to unrelated donor</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="9" rowspan="1">Solid tumors</td></tr><tr><td colspan="1" rowspan="1"> 14-56374</td><td colspan="1" rowspan="1">Hepatoblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">APC</italic>
</td><td colspan="1" rowspan="1">c.3340C &gt; T</td><td colspan="1" rowspan="1">p.R1114</td><td colspan="1" rowspan="1">Nonsense</td><td colspan="1" rowspan="1">Diagnostic; Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Familial adenomatous polyposis</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1"> 15-33544</td><td colspan="1" rowspan="1">Poorly differentiated carcinoma with focal neuroendocrine differentiation</td><td colspan="1" rowspan="1">
<italic toggle="yes">APC (de novo)</italic>
</td><td colspan="1" rowspan="1">c.4660_4661insA</td><td colspan="1" rowspan="1">p.E1554fs</td><td colspan="1" rowspan="1">Frameshift</td><td colspan="1" rowspan="1">Diagnostic; Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Gardner syndrome; Familial adenomatous polyposis</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 15-35162</td><td colspan="1" rowspan="1">Osteosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">RB1</italic>
</td><td colspan="1" rowspan="1">c.1216-3A &gt; G</td><td colspan="1" rowspan="1">p.?</td><td colspan="1" rowspan="1">Splice site</td><td colspan="1" rowspan="1">Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Increased risk for developing other cancers</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1"> 15-44470</td><td colspan="1" rowspan="1">Medulloblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">ATM</italic>
</td><td colspan="1" rowspan="1">c.566G &gt; A; c.8266A &gt; T</td><td colspan="1" rowspan="1">p.R189K; p.K2756*</td><td colspan="1" rowspan="1">Missense, nonsense</td><td colspan="1" rowspan="1">Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Increased risk for developing other cancers</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 15-78886<sup>a</sup>
</td><td colspan="1" rowspan="1">Pineoblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">UGT1A1</italic>
</td><td colspan="1" rowspan="1">*28 allele (“(TA)7TAA”)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Homozygous</td><td colspan="1" rowspan="1">Pharmacogenomic</td><td colspan="1" rowspan="1">Drug sensitivity</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 15-78886<sup>a</sup>
</td><td colspan="1" rowspan="1">Pineoblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">DICER1</italic>
</td><td colspan="1" rowspan="1">c.4807dupC</td><td colspan="1" rowspan="1">p.L1603Pfs</td><td colspan="1" rowspan="1">Frameshift</td><td colspan="1" rowspan="1">Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Risk of ovarian Sertoli-Leydig cell tumor</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 15-17264</td><td colspan="1" rowspan="1">Hepatocellular carcinoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">UGT1A1</italic>
</td><td colspan="1" rowspan="1">*28 allele</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">Pharmacogenomic</td><td colspan="1" rowspan="1">Drug sensitivity</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="9" rowspan="1">ACMG secondary findings</td></tr><tr><td colspan="1" rowspan="1"> 15-29224</td><td colspan="1" rowspan="1">AML</td><td colspan="1" rowspan="1">
<italic toggle="yes">TP53</italic>
</td><td colspan="1" rowspan="1">c. 644G &gt; A</td><td colspan="1" rowspan="1">p.S215N</td><td colspan="1" rowspan="1">Missense</td><td colspan="1" rowspan="1">Affects therapy; Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Explains lack of response to conventional therapy; Increased risk for developing other cancers</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 14-59462</td><td colspan="1" rowspan="1">Nested stromal epithelial tumor of the liver</td><td colspan="1" rowspan="1">
<italic toggle="yes">BRCA1</italic>
</td><td colspan="1" rowspan="1">c.68._69delAG</td><td colspan="1" rowspan="1">p.Glu23Valfs</td><td colspan="1" rowspan="1">Frameshift</td><td colspan="1" rowspan="1">Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 16-88073</td><td colspan="1" rowspan="1">Ependymoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">BRCA1</italic>
</td><td colspan="1" rowspan="1">c.5587_5594delGTAGCACT</td><td colspan="1" rowspan="1">p.V1863Lfs*35</td><td colspan="1" rowspan="1">Frameshift</td><td colspan="1" rowspan="1">Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Breast cancer</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 14-75899</td><td colspan="1" rowspan="1">Neuroblastoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">RYR1</italic>
</td><td colspan="1" rowspan="1">c.6838G &gt; A</td><td colspan="1" rowspan="1">p.V2280I</td><td colspan="1" rowspan="1">Missense</td><td colspan="1" rowspan="1">Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Malignant hyperthermia</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 14-13487</td><td colspan="1" rowspan="1">Osteosarcoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">TNNT2</italic>
</td><td colspan="1" rowspan="1">c.422G &gt; A</td><td colspan="1" rowspan="1">p.Arg141Gln</td><td colspan="1" rowspan="1">Heterozygous</td><td colspan="1" rowspan="1">Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Dilated cardiomyopathy</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"> 15-34296</td><td colspan="1" rowspan="1">Ependymoma</td><td colspan="1" rowspan="1">
<italic toggle="yes">VHL</italic>
</td><td colspan="1" rowspan="1">c.539 T &gt; C</td><td colspan="1" rowspan="1">p.I180T</td><td colspan="1" rowspan="1">Missense</td><td colspan="1" rowspan="1">Health maintenance/ Genetic counseling</td><td colspan="1" rowspan="1">Von Hippel Lindau syndrome</td><td colspan="1" rowspan="1">No</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Same patient</p><p>
<italic toggle="yes">ALL</italic> acute lymphoblastic leukemia, <italic toggle="yes">AMKL</italic> acute megakaryoblastic leukemia, <italic toggle="yes">AML</italic> acute myeloid leukemia, <italic toggle="yes">HLH</italic> hemophagocytic lymphohistiocytosis, <italic toggle="yes">JMML</italic> juvenile myelomonocytic leukemia</p></table-wrap-foot></table-wrap>
</p>
          <p>In patients with hematologic conditions, the incidence of germline alterations related to the primary diagnosis was observed in five patients (15%). A homozygous pathogenic variant in <italic toggle="yes">C1QA</italic> (p.Gln208Ter) diagnostic of C1Q deficiency was identified in a 2-year-old girl with HLH. A homozygous pathogenic variant in <italic toggle="yes">PMS2</italic> (p.S459X) diagnostic of congenital mismatch repair deficiency was identified in one patient with T-cell lymphoblastic lymphoma and consanguineous parentage [<xref ref-type="bibr" rid="CR40">40</xref>]. A likely pathogenic variant in <italic toggle="yes">XIAP</italic> (p.R443P) was identified in a 6-year-old girl with HLH, recurrent EBV infections, and suspected underlying immunodeficiency. Germline testing also revealed a heterozygous pathogenic splicing variant in <italic toggle="yes">RUNX1</italic> (c.806-2A &gt; G, r.Spl) in a patient with AML referred for transplantation for persistent thrombocytopenia following chemotherapy [<xref ref-type="bibr" rid="CR41">41</xref>]. Both an HLA-matched sibling with borderline low platelets and the father were found to carry the same variant. An unrelated donor source was selected. A 2-month-old patient hospitalized for fulminant hemophagocytic syndrome was referred for evaluation of presumed familial HLH and was considered for hematopoietic stem cell transplantation. However, germline WES identified a pathogenic homozygous mutation in <italic toggle="yes">MLL2</italic> (p.M3881Cfs*9) establishing the diagnosis of Kabuki syndrome [<xref ref-type="bibr" rid="CR42">42</xref>] and familial HLH was ruled out due to the lack of alterations in any HLH-associated genes and subsequently plans for a bone marrow transplant were averted.</p>
          <p>ACMG secondary findings were identified in six patients (Table <xref rid="Tab4" ref-type="table">4</xref>) and were returned to the families by clinical genetics. A germline <italic toggle="yes">BRCA1</italic> mutation was discovered in an 18-year-old boy with a rare hepatic tumor and a 17-year-old girl with ependymoma. A <italic toggle="yes">TP53</italic> mutation was found in a 1-year-old girl with AML, a <italic toggle="yes">TNNT2</italic> mutation associated with dilated cardiomyopathy was found in a 15-year-old boy with osteosarcoma, a <italic toggle="yes">RYR1</italic> mutation associated with malignant hyperthermia was found in a 7-year-old girl with neuroblastoma, and a mutation in <italic toggle="yes">VHL</italic> was found in a 2-year-old boy with ependymoma.</p>
          <p>Germline variants classified as VOUS (Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Table S6) were not returned to patients except if they met the following criteria: (1) the variant was predicted to be destructive; (2) the variant was in a well validated cancer-associated gene; and (3) a second somatic alteration was identified or the variant was reduced to homozygosity in the tumor. Clinical genetics returned a VOUS to four patient families meeting these criteria, including an <italic toggle="yes">ITK</italic> (p.V175V) mutation in a 7-year-old girl with Hodgkin lymphoma and Epstein-Barr virus, an <italic toggle="yes">SDHC</italic> (p.G75D) mutation was found in a 12-year-old boy with ALL, a <italic toggle="yes">DICER1</italic> (p.D609Y) mutation in an 18-year-old boy with ALCL, and an <italic toggle="yes">APC</italic> (p.V1822D) mutation in a 7-year-old boy with Ewing sarcoma.</p>
        </sec>
        <sec id="Sec19">
          <title>Clinical impact of WES</title>
          <p>To determine the overall clinical impact of NGS cancer analysis, we evaluated each case as to whether the sequencing data were of potential utility to the referring physician in a clinically meaningful manner. Overall, clinically impactful results were found in 67/101 cases (66%) (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Potentially actionable alterations were found in 38% of cases. In 23% of the cases, the data obtained provided diagnostic significance. Importantly, germline predisposition to cancer was identified in 14% of all cases.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Clinically impactful results. The PIPseq experience yielded clinically impactful results in 67/101 cases. The <italic toggle="yes">Venn diagrams</italic> depict the complexity of overlapping findings within patients. That is, a patient may have a single finding fitting more than one category, whereas another patient may have a finding fitting one category and another finding fitting a different category. For example, results categorized as Targetable/ Diagnostic (n = 6) are as follows: BCR-ABL1; IDH1; PIK3CA; EML4-NTRK3; [STAT5B, KRAS, JAK1/ STAT5B, i7q]; and [TMEM106B-BRAF/ gain chr 7, LOH 9p], with non-bracketed results representing a single finding fitting two categories and results within brackets representing those that were Targetable/ Diagnostic, respectively. Similarly, results categorized as Targetable/ Prognostic (n = 7) are as follows: FOXP1-ABL1; [TET2/ CEBPA]; [H3F3A, FGFR1/ H3F3A]; [NRAS/ MYCN amp, del 1p and 11q, gain 17q]; [c-KIT, TET2, FLT3, NRAS/ CBFB-MYH11]; [KRAS/ No LOH 1p11q]; and [Gain 12q.14.1 involving CDK2/ H3F3A]. Individual patient results are provided in Tables <xref rid="Tab2" ref-type="table">2</xref>, <xref rid="Tab3" ref-type="table">3</xref>, and <xref rid="Tab4" ref-type="table">4</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="13073_2016_389_Fig4_HTML.jpg"/></fig>
</p>
          <p>WES and RNA-seq allows for significant additional analytical endpoints (CNV, fusions, gene expression) over targeted gene panels. Focusing on the 60 cases with full tumor/normal WES and RNA-seq (cWES), the resulting data were clinically impactful in 45 cases (75%) (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). A total of 72 potentially clinically impactful results were found with cWES accounting for 85% of the findings (tumor/normal WES: 45%, <italic toggle="yes">n</italic> = 32; RNA-seq: 40%, <italic toggle="yes">n</italic> = 29) followed by CNV (7%, <italic toggle="yes">n</italic> = 5) and RNA-seq and CNV together in 8% (<italic toggle="yes">n</italic> = 6). Of the 30 potentially targetable aberrations found, 14 were by tumor/normal WES, 15 by RNA-seq, and one by CNV (Fig. <xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Clinical impact of WES and RNA-seq by sequencing technology. Sixty patients had full tumor/normal WES (including CNV) and RNA-seq (cWES) performed. A total of 72 clinically impactful results were found in 45/60 cases (75%). A <italic toggle="yes">pie chart</italic> of the overall clinical impact of cWES is presented on the <italic toggle="yes">left</italic> with a <italic toggle="yes">pie chart</italic> and <italic toggle="yes">table</italic> showing the number of impactful findings by sequencing technology on the <italic toggle="yes">right</italic>. For six patients, CNV and overexpression together yielded prognostic information in four patients with neuroblastoma and two patients with medulloblastoma</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="13073_2016_389_Fig5_HTML.jpg"/></fig>
</p>
        </sec>
      </sec>
      <sec id="Sec20" sec-type="discussion">
        <title>Discussion</title>
        <p>In this report, we reviewed the results of the first 101 patients evaluated in our precision cancer medicine program. While we used a variety of analytical approaches matched to the clinical indications, we primarily utilized a combination of tumor/normal WES and tumor RNA-seq. This platform provided several advantages over targeted cancer gene panels, including the ability to identify translocations, segmental chromosomal changes, and relative gene expression changes.</p>
        <p>Similar to other sequencing efforts in pediatric oncology, we found that the overall mutational load in our patients was relatively low by comparison to adult cancers [<xref ref-type="bibr" rid="CR38">38</xref>]. Of significance, we identified germline alterations that predispose to cancer in 14% of our patients. This is slightly higher than other studies that have demonstrated approximately 8.5–10% frequency of germline risk alleles in pediatric oncology patients and may reflect a selection bias to sequence patients with high-risk cancers [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. These results underscore the need to routinely incorporate germline analysis for pediatric oncology patients.</p>
        <p>Although there is a paucity of Tier 1 actionable alterations in pediatric cancers, using a more lenient definition of actionable which includes same gene–different tumor type, likely pathogenic VOUS, and assessment of both clinical and preclinical data, resulted in the identification of potentially actionable alterations in 38% of all patients. This is comparable to other studies and may in itself be sufficient justification for comprehensive genomic analysis in cancer patients [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Despite this finding, only 16% of patients received matched targeted therapy. The ability to intervene with targeted therapies is particularly challenging for pediatric patients. Many newer drugs lack efficacy data in pediatric diseases or safety data in children and are therefore not yet approved for administration. Additionally, insurance companies are not obligated to provide coverage for the off-label use of these high-cost agents. Compassionate use experimental therapies undergoing clinical testing or recently approved agents for adults are also rarely granted for pediatric patients. Finally, a number of targeted agents are not anticipated to have single-agent efficacy (e.g. MEK inhibition for <italic toggle="yes">RAS</italic> mutant tumors). Together, the lack of pediatric experience and opportunities with combination therapy represent additional constraints in pediatric oncology.</p>
        <p>Nevertheless, we believe that narrowing the definition of benefit to the identification of actionable targets and matched targeted therapy underestimates the potential clinical utility of comprehensive genomic analysis. We provide examples of genomic alterations that are not actionable per se, but which have significant clinical impact including for diagnostic, prognostic, or pharmacogenomics purposes. Taking a broad view of clinical impact, it is notable that the data from our sequencing platform impacted clinical decision-making in over two-thirds of all cases. With the increase in genomic medicine programs and the growing body of knowledge, the adoption of a more inclusive definition of clinical utility that does not narrowly focus on drug selection for patients with a specific biomarker is an important point to consider when incorporating NGS technologies into clinical practice.</p>
        <p>Most cancer sequencing programs focus on interrogation of tumor DNA. It is notable that in our program the transcriptome data were responsible for a number of clinically impactful calls that were not evident from interrogating the DNA alone. In addition to verifying variants identified in the DNA analysis, the transcriptome was used to identify translocations and was mined to identify signaling pathway activity. We generated a model from transcriptomes in our database, allowing us to identify expression outliers. We were also able to project the gene expression data into existing gene expression datasets for classification purposes, allowing us for example, to identify a <italic toggle="yes">BCR-ABL1</italic>-like gene expression pattern. Therefore, assessing tumor RNA is an important component of comprehensive genomic approaches and in our series samples interrogated with both WES and RNA-seq characterization resulted in clinically impactful data in 75% of cases.</p>
        <p>The importance of assessing germline in addition to cancer DNA is evident from the 14% incidence of germline variants that may predispose to cancer. These findings clearly have broad implications that impact not only the patient but potentially the entire family. Moreover, the identification of germline risk offers opportunities for prevention and early screening and detection. It is notable that given the opportunity to opt out of this knowledge, nearly all families actively choose for the return of these results, underscoring the fallacy of the paternalistic view that families need to be protected from learning these findings.</p>
        <p>Finally, extending beyond a fuller appreciation for the potential clinical impact of sequencing technologies, it is important to consider that genomic approaches do not just provide incremental data, but may replace many conventional tests. Currently, many genetic alterations can be identified by standard approaches, such as karyotype and FISH, and with faster turnaround times. Similarly, existing NGS panels, which allow the detection of mutations and/or fusions of clear clinical relevance, may be adequate in certain clinical scenarios. Nevertheless, in an era where initial diagnostic biopsies are often performed through minimally invasive approaches, there is a compelling argument to utilize comprehensive approaches with minimal tissue requirements. As the cost of NGS declines, the ability to comprehensively interrogate the genome may supersede the need for sequential, potentially tissue-exhausting directed testing, with the added benefit of uncovering rare targetable and potentially unexpected genomic drivers.</p>
      </sec>
      <sec id="Sec21" sec-type="conclusion">
        <title>Conclusions</title>
        <p>Our results demonstrate the feasibility of incorporating clinical NGS into pediatric hematology-oncology practice. While the frequency of finding actionable alterations is consistent with reports of other pediatric oncology sequencing endeavors [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], we feel this singular attribute grossly underestimates the potential clinical utility of these data. The ability to avoid ineffective/inappropriate therapies, to solidify a definitive diagnosis, and to identify pharmacogenomics modifiers all have clinical impact. Taking this more inclusive view, it is striking that the sequencing data were found to be clinically impactful in 66% of all cases tested through our program and in 75% of cases comprehensively assessed using cWES and RNA-seq. The value proposition for next generation diagnostics, therefore, should be measured both on the clinical impact of the data and the ability to replace multiple conventional single endpoint assays with a single comprehensive view of the genome.</p>
      </sec>
    </body>
    <back>
      <app-group>
        <app id="App1">
          <sec id="Sec22">
            <title>Additional files</title>
            <p>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="13073_2016_389_MOESM1_ESM.pdf" id="MOESM1" orientation="portrait"><label>Additional file 1:</label><caption><p>A PDF file containing Supplementary Methods. Supplementary Methods DNA and RNA extraction; somatic variant calling strategy; CNV; transcriptome analysis. (PDF 82 kb)</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="13073_2016_389_MOESM2_ESM.pdf" id="MOESM2" orientation="portrait"><label>Additional file 2:</label><caption><p>A PDF file containing Supplementary Tables S1–S5. <bold>Table S1</bold> Quality statistics for WES. <bold>Table S2</bold> Accession ID for all genes and fusions referenced in the manuscript. <bold>Table S3</bold> Individual diagnoses. <bold>Table S4</bold> Cancer WES consent preferences. <bold>Table S5</bold> Reported somatic alterations by tier and germline alterations by category. (PDF 240 kb)</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="13073_2016_389_MOESM3_ESM.pdf" id="MOESM3" orientation="portrait"><label>Additional file 3:</label><caption><p>De-identified clinical cWES report. (PDF 157 kb)</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="13073_2016_389_MOESM4_ESM.tif" id="MOESM4" orientation="portrait"><label>Additional file 4:</label><caption><p>A TIFF file containing Supplementary Figure S1. <bold>Figure S1</bold> Total somatic mutation load across all patients. The total mutational load across patients was 19,308 variants (mean, 216.9; SD, 829.3; median, 69). By diagnostic category, the total mutational load for solid tumors was 5853 variants (mean, 97.5; SD, 111.7; median, 86; range, 15–881), and for hematologic conditions was 13,455 variants (mean, 463.9; SD, 1428.8; median, 52; range, 14–5950). (TIF 845 kb)</p></caption></media>
<media xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="13073_2016_389_MOESM5_ESM.xlsx" id="MOESM5" orientation="portrait"><label>Additional file 5:</label><caption><p>An excel file containing Supplementary Table S6. <bold>Table S6</bold> Somatic and germline variants of unknown significance. (XLSX 20 kb)</p></caption></media>
</p>
          </sec>
        </app>
      </app-group>
      <glossary>
        <title>Abbreviations</title>
        <def-list>
          <def-item>
            <term>ACMG</term>
            <def>
              <p>American College of Medical Genetics</p>
            </def>
          </def-item>
          <def-item>
            <term>CNV</term>
            <def>
              <p>copy number variation</p>
            </def>
          </def-item>
          <def-item>
            <term>cWES</term>
            <def>
              <p>cancer whole exome sequencing</p>
            </def>
          </def-item>
          <def-item>
            <term>EMR</term>
            <def>
              <p>electronic medical record</p>
            </def>
          </def-item>
          <def-item>
            <term>FFPE</term>
            <def>
              <p>formalin fixed paraffin embedded</p>
            </def>
          </def-item>
          <def-item>
            <term>HLA</term>
            <def>
              <p>human leukocyte antigen</p>
            </def>
          </def-item>
          <def-item>
            <term>HLH</term>
            <def>
              <p>hemophagocytic lymphohistiocytosis</p>
            </def>
          </def-item>
          <def-item>
            <term>VOUS</term>
            <def>
              <p>variants of uncertain significance</p>
            </def>
          </def-item>
          <def-item>
            <term>WES</term>
            <def>
              <p>whole exome sequencing</p>
            </def>
          </def-item>
        </def-list>
      </glossary>
      <ack>
        <title>Acknowledgements</title>
        <p>The authors are grateful to the patients, their families, and to the doctors and nurses at Columbia University Medical Center.</p>
        <sec id="FPar1">
          <title>Funding</title>
          <p>The present work was supported by the Sohn Conference Foundation (ALK, JGB), Hyundai Hope on Wheels (JAO, JGB, ALK), Alex’s Lemonade Stand Foundation (JGB, RJZ, DD), Pediatric Cancer Foundation (JGB, JAO), Taybandz/ Conquering Kidz Cancer (DJY, JGB), Jamie Deutsch Foundation (JGB, FDC), and Hope and Heroes (JAO, JGB, ALK). We would also like to thank and acknowledge funding and resources from the Herbert Irving Comprehensive Cancer Center.</p>
        </sec>
        <sec id="FPar2">
          <title>Availability of data and materials</title>
          <p>The dataset supporting the conclusions of this article can be obtained from the cBioPortal for Cancer Genomics (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cbioportal.org/">http://cbioportal.org</ext-link>) by selecting the DATA SETS tab and clicking on the citation listed in the Reference column. In accordance with CUMC IRB approval, vcf files, translocations, and gene expression data are available through the cBioPortal.</p>
        </sec>
        <sec id="FPar3">
          <title>Authors’ contributions</title>
          <p>JAO, JGB, MLS, and ALK conceived, designed, and supervised all phases of the project. DP, ANS, and RZ provided coordination of clinical samples and testing. MMM and PLN directed the clinical laboratory and oversaw sample preparation, data processing, and computational analysis. HH and HR provided interpretation of clinical analysis. MMM, SJH, and AT carried out clinical analysis, interpretation, and reporting to the EMR. JGB, MLS, FSDC, JHG, DJY, and ALK provided clinical expertise and interpretation of clinical sequencing data at the multi-disciplinary tumor board and were responsible for overseeing consent and return of results. WKC provided critical advice on the return of germline findings and provided oversight of genetic counseling. CK provided genetic counseling. SJA and JP carried out data processing and computational analysis. DD provided bioinformatics support. JAO, JGB, SGE, and ALK provided funding acquisition. JAO, JGB, MLS, and ALK wrote the paper. JAO, JGB, MLS, JHG, DY, FDC, DD, WKC, KC, ANS, MMM, and ALK revised the paper. All authors contributed to data interpretation, discussions, and editing of the paper. All authors read and approved the final manuscript.</p>
        </sec>
        <sec id="FPar4">
          <title>Competing interests</title>
          <p>The authors declare that they have no competing interests.</p>
        </sec>
        <sec id="FPar5">
          <title>Consent for publication</title>
          <p>This retrospective review and publication of results from all consenting participants was approved by the CUMC IRB (IRB# AAAQ8170 and AAAP1200).</p>
        </sec>
        <sec id="FPar6">
          <title>Ethics approval and consent to participate</title>
          <p>All participants provided written informed consent for tumor and/or germline sequencing analysis. Participants signed either a Columbia University Medical Center (CUMC) Institutional Review Board (IRB) approved consent (IRB# AAAB7109 or AAAJ5811) or clinical consent. Our research was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP).</p>
        </sec>
      </ack>
      <ref-list id="Bib1">
        <title>References</title>
        <ref id="CR1">
          <label>1.</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Murphy</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Kochanek</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <source>Deaths: Final Data for 2010. National vital statistics reports, vol. 61 no 4</source>
            <year>2013</year>
            <publisher-loc>Hyattsville, MD</publisher-loc>
            <publisher-name>National Center for Health Statistics</publisher-name>
            <pub-id pub-id-type="pmid">24979972</pub-id>
          </element-citation>
        </ref>
        <ref id="CR2">
          <label>2.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Oeffinger</surname>
                <given-names>KC</given-names>
              </name>
              <name name-style="western">
                <surname>Mertens</surname>
                <given-names>AC</given-names>
              </name>
              <name name-style="western">
                <surname>Sklar</surname>
                <given-names>CA</given-names>
              </name>
              <name name-style="western">
                <surname>Kawashima</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Hudson</surname>
                <given-names>MM</given-names>
              </name>
              <name name-style="western">
                <surname>Meadows</surname>
                <given-names>AT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Chronic health conditions in adult survivors of childhood cancer</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <volume>355</volume>
            <issue>15</issue>
            <fpage>1572</fpage>
            <lpage>1582</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMsa060185</pub-id>
            <pub-id pub-id-type="pmid">17035650</pub-id>
          </element-citation>
        </ref>
        <ref id="CR3">
          <label>3.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hunger</surname>
                <given-names>SP</given-names>
              </name>
              <name name-style="western">
                <surname>Mullighan</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Acute lymphoblastic leukemia in children</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <volume>373</volume>
            <issue>16</issue>
            <fpage>1541</fpage>
            <lpage>1552</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMra1400972</pub-id>
            <pub-id pub-id-type="pmid">26465987</pub-id>
          </element-citation>
        </ref>
        <ref id="CR4">
          <label>4.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pinto</surname>
                <given-names>NR</given-names>
              </name>
              <name name-style="western">
                <surname>Applebaum</surname>
                <given-names>MA</given-names>
              </name>
              <name name-style="western">
                <surname>Volchenboum</surname>
                <given-names>SL</given-names>
              </name>
              <name name-style="western">
                <surname>Matthay</surname>
                <given-names>KK</given-names>
              </name>
              <name name-style="western">
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name name-style="western">
                <surname>Ambros</surname>
                <given-names>PF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Advances in risk classification and treatment strategies for neuroblastoma</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <volume>33</volume>
            <issue>27</issue>
            <fpage>3008</fpage>
            <lpage>3017</lpage>
            <pub-id pub-id-type="doi">10.1200/JCO.2014.59.4648</pub-id>
            <pub-id pub-id-type="pmid">26304901</pub-id>
            <pub-id pub-id-type="pmcid">PMC4567703</pub-id>
          </element-citation>
        </ref>
        <ref id="CR5">
          <label>5.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Beltran</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Eng</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Mosquera</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Sigaras</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Romanel</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Rennert</surname>
                <given-names>H</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Whole-exome sequencing of metastatic cancer and biomarkers of treatment response</article-title>
            <source>JAMA Oncol</source>
            <year>2015</year>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>466</fpage>
            <lpage>474</lpage>
            <pub-id pub-id-type="doi">10.1001/jamaoncol.2015.1313</pub-id>
            <pub-id pub-id-type="pmid">26181256</pub-id>
            <pub-id pub-id-type="pmcid">PMC4505739</pub-id>
          </element-citation>
        </ref>
        <ref id="CR6">
          <label>6.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Frampton</surname>
                <given-names>GM</given-names>
              </name>
              <name name-style="western">
                <surname>Fichtenholtz</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Otto</surname>
                <given-names>GA</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Downing</surname>
                <given-names>SR</given-names>
              </name>
              <name name-style="western">
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing</article-title>
            <source>Nat Biotech</source>
            <year>2013</year>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>1023</fpage>
            <lpage>1031</lpage>
            <pub-id pub-id-type="doi">10.1038/nbt.2696</pub-id>
            <pub-id pub-id-type="pmcid">PMC5710001</pub-id>
            <pub-id pub-id-type="pmid">24142049</pub-id>
          </element-citation>
        </ref>
        <ref id="CR7">
          <label>7.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hovelson</surname>
                <given-names>DH</given-names>
              </name>
              <name name-style="western">
                <surname>McDaniel</surname>
                <given-names>AS</given-names>
              </name>
              <name name-style="western">
                <surname>Cani</surname>
                <given-names>AK</given-names>
              </name>
              <name name-style="western">
                <surname>Johnson</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Rhodes</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Williams</surname>
                <given-names>PD</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors</article-title>
            <source>Neoplasia</source>
            <year>2015</year>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>385</fpage>
            <lpage>399</lpage>
            <pub-id pub-id-type="doi">10.1016/j.neo.2015.03.004</pub-id>
            <pub-id pub-id-type="pmid">25925381</pub-id>
            <pub-id pub-id-type="pmcid">PMC4415141</pub-id>
          </element-citation>
        </ref>
        <ref id="CR8">
          <label>8.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lanman</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Mortimer</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Zill</surname>
                <given-names>O</given-names>
              </name>
              <name name-style="western">
                <surname>Sebisanovic</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Lopez</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Blau</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA</article-title>
            <source>PLoS ONE</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>e0140712</fpage>
            <pub-id pub-id-type="doi">10.1371/journal.pone.0140712</pub-id>
            <pub-id pub-id-type="pmid">26474073</pub-id>
            <pub-id pub-id-type="pmcid">PMC4608804</pub-id>
          </element-citation>
        </ref>
        <ref id="CR9">
          <label>9.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Meric-Bernstam</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Brusco</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Shaw</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Horombe</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Kopetz</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Davies</surname>
                <given-names>MA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <volume>33</volume>
            <issue>25</issue>
            <fpage>2753</fpage>
            <lpage>2762</lpage>
            <pub-id pub-id-type="doi">10.1200/JCO.2014.60.4165</pub-id>
            <pub-id pub-id-type="pmid">26014291</pub-id>
            <pub-id pub-id-type="pmcid">PMC4550690</pub-id>
          </element-citation>
        </ref>
        <ref id="CR10">
          <label>10.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mody</surname>
                <given-names>RJ</given-names>
              </name>
              <name name-style="western">
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Lonigro</surname>
                <given-names>RJ</given-names>
              </name>
              <name name-style="western">
                <surname>Cao</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>Roychowdhury</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Vats</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrative clinical sequencing in the management of refractory or relapsed cancer in youth</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <volume>314</volume>
            <issue>9</issue>
            <fpage>913</fpage>
            <lpage>925</lpage>
            <pub-id pub-id-type="doi">10.1001/jama.2015.10080</pub-id>
            <pub-id pub-id-type="pmid">26325560</pub-id>
            <pub-id pub-id-type="pmcid">PMC4758114</pub-id>
          </element-citation>
        </ref>
        <ref id="CR11">
          <label>11.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ortiz</surname>
                <given-names>MV</given-names>
              </name>
              <name name-style="western">
                <surname>Kobos</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Slotkin</surname>
                <given-names>EK</given-names>
              </name>
              <name name-style="western">
                <surname>Roberts</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Berger</surname>
                <given-names>MF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrating genomics into clinical pediatric oncology using the molecular tumor board at the Memorial Sloan Kettering Cancer Center</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2016</year>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>1368</fpage>
            <lpage>1374</lpage>
            <pub-id pub-id-type="doi">10.1002/pbc.26002</pub-id>
            <pub-id pub-id-type="pmid">27082517</pub-id>
            <pub-id pub-id-type="pmcid">PMC5429592</pub-id>
          </element-citation>
        </ref>
        <ref id="CR12">
          <label>12.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Parsons</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Roy</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Scollon</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Bergstrom</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors</article-title>
            <source>JAMA Oncol</source>
            <year>2016</year>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>616</fpage>
            <lpage>624</lpage>
            <pub-id pub-id-type="doi">10.1001/jamaoncol.2015.5699</pub-id>
            <pub-id pub-id-type="pmcid">PMC5471125</pub-id>
            <pub-id pub-id-type="pmid">26822237</pub-id>
          </element-citation>
        </ref>
        <ref id="CR13">
          <label>13.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shao</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Wan</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name name-style="western">
                <surname>Cheng</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma</article-title>
            <source>Sci Rep.</source>
            <year>2016</year>
            <volume>6</volume>
            <fpage>22338</fpage>
            <pub-id pub-id-type="doi">10.1038/srep22338</pub-id>
            <pub-id pub-id-type="pmid">26936516</pub-id>
            <pub-id pub-id-type="pmcid">PMC4776238</pub-id>
          </element-citation>
        </ref>
        <ref id="CR14">
          <label>14.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Uzilov</surname>
                <given-names>AV</given-names>
              </name>
              <name name-style="western">
                <surname>Ding</surname>
                <given-names>W</given-names>
              </name>
              <name name-style="western">
                <surname>Fink</surname>
                <given-names>MY</given-names>
              </name>
              <name name-style="western">
                <surname>Antipin</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Brohl</surname>
                <given-names>AS</given-names>
              </name>
              <name name-style="western">
                <surname>Davis</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Development and clinical application of an integrative genomic approach to personalized cancer therapy</article-title>
            <source>Genome Med</source>
            <year>2016</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <lpage>20</lpage>
            <pub-id pub-id-type="doi">10.1186/s13073-016-0313-0</pub-id>
            <pub-id pub-id-type="pmid">27245685</pub-id>
            <pub-id pub-id-type="pmcid">PMC4888213</pub-id>
          </element-citation>
        </ref>
        <ref id="CR15">
          <label>15.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Harris</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>DuBois</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Glade Bender</surname>
                <given-names>JL</given-names>
              </name>
              <name name-style="western">
                <surname>Kim</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Crompton</surname>
                <given-names>BD</given-names>
              </name>
              <name name-style="western">
                <surname>Parker</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: The individualized cancer therapy (icat) study</article-title>
            <source>JAMA Oncol</source>
            <year>2016</year>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>608</fpage>
            <lpage>615</lpage>
            <pub-id pub-id-type="doi">10.1001/jamaoncol.2015.5689</pub-id>
            <pub-id pub-id-type="pmid">26822149</pub-id>
          </element-citation>
        </ref>
        <ref id="CR16">
          <label>16.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <collab>ACMG Board of Directors</collab>
            </person-group>
            <article-title>Points to consider in the clinical application of genomic sequencing</article-title>
            <source>Genet Med</source>
            <year>2012</year>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>759</fpage>
            <lpage>761</lpage>
            <pub-id pub-id-type="doi">10.1038/gim.2012.74</pub-id>
            <pub-id pub-id-type="pmid">22863877</pub-id>
          </element-citation>
        </ref>
        <ref id="CR17">
          <label>17.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Green</surname>
                <given-names>RC</given-names>
              </name>
              <name name-style="western">
                <surname>Berg</surname>
                <given-names>JS</given-names>
              </name>
              <name name-style="western">
                <surname>Grody</surname>
                <given-names>WW</given-names>
              </name>
              <name name-style="western">
                <surname>Kalia</surname>
                <given-names>SS</given-names>
              </name>
              <name name-style="western">
                <surname>Korf</surname>
                <given-names>BR</given-names>
              </name>
              <name name-style="western">
                <surname>Martin</surname>
                <given-names>CL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing</article-title>
            <source>Genet Med</source>
            <year>2013</year>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>565</fpage>
            <lpage>574</lpage>
            <pub-id pub-id-type="doi">10.1038/gim.2013.73</pub-id>
            <pub-id pub-id-type="pmid">23788249</pub-id>
            <pub-id pub-id-type="pmcid">PMC3727274</pub-id>
          </element-citation>
        </ref>
        <ref id="CR18">
          <label>18.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Magi</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Tattini</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Cifola</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>D’Aurizio</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Benelli</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Mangano</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>EXCAVATOR: detecting copy number variants from whole-exome sequencing data</article-title>
            <source>Genome Biol</source>
            <year>2013</year>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>R120</fpage>
            <pub-id pub-id-type="doi">10.1186/gb-2013-14-10-r120</pub-id>
            <pub-id pub-id-type="pmid">24172663</pub-id>
            <pub-id pub-id-type="pmcid">PMC4053953</pub-id>
          </element-citation>
        </ref>
        <ref id="CR19">
          <label>19.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Trapnell</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Roberts</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Goff</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Pertea</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Kim</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Kelley</surname>
                <given-names>DR</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title>
            <source>Nat Protoc</source>
            <year>2012</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>562</fpage>
            <lpage>578</lpage>
            <pub-id pub-id-type="doi">10.1038/nprot.2012.016</pub-id>
            <pub-id pub-id-type="pmid">22383036</pub-id>
            <pub-id pub-id-type="pmcid">PMC3334321</pub-id>
          </element-citation>
        </ref>
        <ref id="CR20">
          <label>20.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Trapnell</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Roberts</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Goff</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Pertea</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Kim</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Kelley</surname>
                <given-names>DR</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Corrigendum: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title>
            <source>Nat Protoc</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>2513</fpage>
            <pub-id pub-id-type="doi">10.1038/nprot1014-2513a</pub-id>
            <pub-id pub-id-type="pmcid">PMC3334321</pub-id>
            <pub-id pub-id-type="pmid">22383036</pub-id>
          </element-citation>
        </ref>
        <ref id="CR21">
          <label>21.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ge</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Juan</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Fang</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Newman</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Hoeck</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution</article-title>
            <source>Bioinformatics</source>
            <year>2011</year>
            <volume>27</volume>
            <issue>14</issue>
            <fpage>1922</fpage>
            <lpage>1928</lpage>
            <pub-id pub-id-type="doi">10.1093/bioinformatics/btr310</pub-id>
            <pub-id pub-id-type="pmid">21593131</pub-id>
          </element-citation>
        </ref>
        <ref id="CR22">
          <label>22.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ramsköld</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>ET</given-names>
              </name>
              <name name-style="western">
                <surname>Burge</surname>
                <given-names>CB</given-names>
              </name>
              <name name-style="western">
                <surname>Sandberg</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>An abundance of ubiquitously expressed genes revealed by tissue transcriptome sequence data</article-title>
            <source>PLoS Comput Biol</source>
            <year>2009</year>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>e1000598</fpage>
            <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000598</pub-id>
            <pub-id pub-id-type="pmid">20011106</pub-id>
            <pub-id pub-id-type="pmcid">PMC2781110</pub-id>
          </element-citation>
        </ref>
        <ref id="CR23">
          <label>23.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cerami</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Dogrusoz</surname>
                <given-names>U</given-names>
              </name>
              <name name-style="western">
                <surname>Gross</surname>
                <given-names>BE</given-names>
              </name>
              <name name-style="western">
                <surname>Sumer</surname>
                <given-names>SO</given-names>
              </name>
              <name name-style="western">
                <surname>Aksoy</surname>
                <given-names>BA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title>
            <source>Cancer Discov</source>
            <year>2012</year>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>401</fpage>
            <lpage>404</lpage>
            <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id>
            <pub-id pub-id-type="pmid">22588877</pub-id>
            <pub-id pub-id-type="pmcid">PMC3956037</pub-id>
          </element-citation>
        </ref>
        <ref id="CR24">
          <label>24.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Aksoy</surname>
                <given-names>BA</given-names>
              </name>
              <name name-style="western">
                <surname>Dogrusoz</surname>
                <given-names>U</given-names>
              </name>
              <name name-style="western">
                <surname>Dresdner</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Gross</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Sumer</surname>
                <given-names>SO</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>
            <source>Sci Signal</source>
            <year>2013</year>
            <volume>6</volume>
            <issue>269</issue>
            <fpage>l1</fpage>
            <pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id>
            <pub-id pub-id-type="pmcid">PMC4160307</pub-id>
            <pub-id pub-id-type="pmid">23550210</pub-id>
          </element-citation>
        </ref>
        <ref id="CR25">
          <label>25.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Joseph</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Cankovic</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Caughron</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Chandra</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Emmadi</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Hagenkord</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The spectrum of clinical utilities in molecular pathology testing procedures for inherited conditions and cancer</article-title>
            <source>J Mol Diagn</source>
            <year>2016</year>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>605</fpage>
            <lpage>619</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jmoldx.2016.05.007</pub-id>
            <pub-id pub-id-type="pmid">27542512</pub-id>
          </element-citation>
        </ref>
        <ref id="CR26">
          <label>26.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wagle</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Berger</surname>
                <given-names>MF</given-names>
              </name>
              <name name-style="western">
                <surname>Davis</surname>
                <given-names>MJ</given-names>
              </name>
              <name name-style="western">
                <surname>Blumenstiel</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Defelice</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Pochanard</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing</article-title>
            <source>Cancer Discov</source>
            <year>2012</year>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>82</fpage>
            <lpage>93</lpage>
            <pub-id pub-id-type="doi">10.1158/2159-8290.CD-11-0184</pub-id>
            <pub-id pub-id-type="pmid">22585170</pub-id>
            <pub-id pub-id-type="pmcid">PMC3353152</pub-id>
          </element-citation>
        </ref>
        <ref id="CR27">
          <label>27.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kinoshita</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Hirota</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Isozaki</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Nishitani</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Tsutsui</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Watabe</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Characterization of tyrosine kinase I domain c-kit gene mutation Asn655Lys newly found in primary jejunal gastrointestinal stromal tumor</article-title>
            <source>Am J Gastroenterol</source>
            <year>2007</year>
            <volume>102</volume>
            <issue>5</issue>
            <fpage>1134</fpage>
            <lpage>1136</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1572-0241.2007.01180_11.x</pub-id>
            <pub-id pub-id-type="pmid">17489795</pub-id>
          </element-citation>
        </ref>
        <ref id="CR28">
          <label>28.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mullighan</surname>
                <given-names>CG</given-names>
              </name>
              <name name-style="western">
                <surname>Su</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Radtke</surname>
                <given-names>I</given-names>
              </name>
              <name name-style="western">
                <surname>Phillips</surname>
                <given-names>LA</given-names>
              </name>
              <name name-style="western">
                <surname>Miller</surname>
                <given-names>CB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <volume>360</volume>
            <issue>5</issue>
            <fpage>470</fpage>
            <lpage>480</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa0808253</pub-id>
            <pub-id pub-id-type="pmid">19129520</pub-id>
            <pub-id pub-id-type="pmcid">PMC2674612</pub-id>
          </element-citation>
        </ref>
        <ref id="CR29">
          <label>29.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Roberts</surname>
                <given-names>KG</given-names>
              </name>
              <name name-style="western">
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Payne-Turner</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Harvey</surname>
                <given-names>RC</given-names>
              </name>
              <name name-style="western">
                <surname>Yang</surname>
                <given-names>YL</given-names>
              </name>
              <name name-style="western">
                <surname>Pei</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <volume>371</volume>
            <issue>11</issue>
            <fpage>1005</fpage>
            <lpage>1015</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa1403088</pub-id>
            <pub-id pub-id-type="pmid">25207766</pub-id>
            <pub-id pub-id-type="pmcid">PMC4191900</pub-id>
          </element-citation>
        </ref>
        <ref id="CR30">
          <label>30.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Küçük</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Jiang</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Hu</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name name-style="western">
                <surname>Chan</surname>
                <given-names>JK</given-names>
              </name>
              <name name-style="western">
                <surname>Xiao</surname>
                <given-names>W</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells</article-title>
            <source>Nat Commun.</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>6025</fpage>
            <pub-id pub-id-type="doi">10.1038/ncomms7025</pub-id>
            <pub-id pub-id-type="pmid">25586472</pub-id>
            <pub-id pub-id-type="pmcid">PMC7743911</pub-id>
          </element-citation>
        </ref>
        <ref id="CR31">
          <label>31.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tartaglia</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Niemeyer</surname>
                <given-names>CM</given-names>
              </name>
              <name name-style="western">
                <surname>Fragale</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Song</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>Buechner</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Jung</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia</article-title>
            <source>Nat Genet</source>
            <year>2003</year>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>148</fpage>
            <lpage>150</lpage>
            <pub-id pub-id-type="doi">10.1038/ng1156</pub-id>
            <pub-id pub-id-type="pmid">12717436</pub-id>
          </element-citation>
        </ref>
        <ref id="CR32">
          <label>32.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Meyer</surname>
                <given-names>JA</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Hogan</surname>
                <given-names>LE</given-names>
              </name>
              <name name-style="western">
                <surname>Yang</surname>
                <given-names>JJ</given-names>
              </name>
              <name name-style="western">
                <surname>Dandekar</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Patel</surname>
                <given-names>JP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia</article-title>
            <source>Nat Genet</source>
            <year>2013</year>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>290</fpage>
            <lpage>294</lpage>
            <pub-id pub-id-type="doi">10.1038/ng.2558</pub-id>
            <pub-id pub-id-type="pmid">23377183</pub-id>
            <pub-id pub-id-type="pmcid">PMC3681285</pub-id>
          </element-citation>
        </ref>
        <ref id="CR33">
          <label>33.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tzoneva</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Perez-Garcia</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Carpenter</surname>
                <given-names>Z</given-names>
              </name>
              <name name-style="western">
                <surname>Khiabanian</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Tosello</surname>
                <given-names>V</given-names>
              </name>
              <name name-style="western">
                <surname>Allegretta</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL</article-title>
            <source>Nat Med</source>
            <year>2013</year>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>368</fpage>
            <lpage>371</lpage>
            <pub-id pub-id-type="doi">10.1038/nm.3078</pub-id>
            <pub-id pub-id-type="pmid">23377281</pub-id>
            <pub-id pub-id-type="pmcid">PMC3594483</pub-id>
          </element-citation>
        </ref>
        <ref id="CR34">
          <label>34.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tannenbaum-Dvir</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Glade Bender</surname>
                <given-names>JL</given-names>
              </name>
              <name name-style="western">
                <surname>Church</surname>
                <given-names>AJ</given-names>
              </name>
              <name name-style="western">
                <surname>Janeway</surname>
                <given-names>KA</given-names>
              </name>
              <name name-style="western">
                <surname>Harris</surname>
                <given-names>MH</given-names>
              </name>
              <name name-style="western">
                <surname>Manuskhani</surname>
                <given-names>MM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma</article-title>
            <source>Cold Spring Harb Mol Case Stud</source>
            <year>2015</year>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>a000471</fpage>
            <pub-id pub-id-type="doi">10.1101/mcs.a000471</pub-id>
            <pub-id pub-id-type="pmid">27148571</pub-id>
            <pub-id pub-id-type="pmcid">PMC4850889</pub-id>
          </element-citation>
        </ref>
        <ref id="CR35">
          <label>35.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gruber Tanja</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Larson Gedman</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Koss</surname>
                <given-names>CS</given-names>
              </name>
              <name name-style="western">
                <surname>Marada</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Ta</surname>
                <given-names>HQ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia</article-title>
            <source>Cancer Cell</source>
            <year>2012</year>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>683</fpage>
            <lpage>697</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2012.10.007</pub-id>
            <pub-id pub-id-type="pmid">23153540</pub-id>
            <pub-id pub-id-type="pmcid">PMC3547667</pub-id>
          </element-citation>
        </ref>
        <ref id="CR36">
          <label>36.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ohali</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Avigad</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Zaizov</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Ophir</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Horn-Saban</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Cohen</surname>
                <given-names>IJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Prediction of high risk Ewing’s sarcoma by gene expression profiling</article-title>
            <source>Oncogene</source>
            <year>2004</year>
            <volume>23</volume>
            <issue>55</issue>
            <fpage>8997</fpage>
            <lpage>9006</lpage>
            <pub-id pub-id-type="doi">10.1038/sj.onc.1208060</pub-id>
            <pub-id pub-id-type="pmid">15467746</pub-id>
          </element-citation>
        </ref>
        <ref id="CR37">
          <label>37.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Witt</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Mack</surname>
                <given-names>SC</given-names>
              </name>
              <name name-style="western">
                <surname>Ryzhova</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Bender</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Sill</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Isserlin</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma</article-title>
            <source>Cancer Cell</source>
            <year>2011</year>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <lpage>157</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2011.07.007</pub-id>
            <pub-id pub-id-type="pmid">21840481</pub-id>
            <pub-id pub-id-type="pmcid">PMC4154494</pub-id>
          </element-citation>
        </ref>
        <ref id="CR38">
          <label>38.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Alexandrov</surname>
                <given-names>LB</given-names>
              </name>
              <name name-style="western">
                <surname>Nik-Zainal</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Wedge</surname>
                <given-names>DC</given-names>
              </name>
              <name name-style="western">
                <surname>Aparicio</surname>
                <given-names>SA</given-names>
              </name>
              <name name-style="western">
                <surname>Behjati</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Biankin</surname>
                <given-names>AV</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Signatures of mutational processes in human cancer</article-title>
            <source>Nature</source>
            <year>2013</year>
            <volume>500</volume>
            <issue>7463</issue>
            <fpage>415</fpage>
            <lpage>421</lpage>
            <pub-id pub-id-type="doi">10.1038/nature12477</pub-id>
            <pub-id pub-id-type="pmid">23945592</pub-id>
            <pub-id pub-id-type="pmcid">PMC3776390</pub-id>
          </element-citation>
        </ref>
        <ref id="CR39">
          <label>39.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tamaska</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Adam</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Kozma</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Gopcsa</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Andrikovics</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Tordai</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Hepatosplenic γδ T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration</article-title>
            <source>Virchows Arch</source>
            <year>2006</year>
            <volume>449</volume>
            <issue>4</issue>
            <fpage>479</fpage>
            <lpage>483</lpage>
            <pub-id pub-id-type="doi">10.1007/s00428-006-0267-5</pub-id>
            <pub-id pub-id-type="pmid">16941150</pub-id>
          </element-citation>
        </ref>
        <ref id="CR40">
          <label>40.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Durno</surname>
                <given-names>CA</given-names>
              </name>
              <name name-style="western">
                <surname>Sherman</surname>
                <given-names>PM</given-names>
              </name>
              <name name-style="western">
                <surname>Aronson</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Malkin</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Hawkins</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Bakry</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome</article-title>
            <source>Eur J Cancer</source>
            <year>2015</year>
            <volume>51</volume>
            <issue>8</issue>
            <fpage>977</fpage>
            <lpage>983</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ejca.2015.02.008</pub-id>
            <pub-id pub-id-type="pmid">25883011</pub-id>
          </element-citation>
        </ref>
        <ref id="CR41">
          <label>41.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Song</surname>
                <given-names>WJ</given-names>
              </name>
              <name name-style="western">
                <surname>Sullivan</surname>
                <given-names>MG</given-names>
              </name>
              <name name-style="western">
                <surname>Legare</surname>
                <given-names>RD</given-names>
              </name>
              <name name-style="western">
                <surname>Hutchings</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Tan</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>Kufrin</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia</article-title>
            <source>Nat Genet</source>
            <year>1999</year>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>166</fpage>
            <lpage>175</lpage>
            <pub-id pub-id-type="doi">10.1038/13793</pub-id>
            <pub-id pub-id-type="pmid">10508512</pub-id>
          </element-citation>
        </ref>
        <ref id="CR42">
          <label>42.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Miyake</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Koshimizu</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Okamoto</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Mizuno</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Ogata</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Nagai</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>MLL2 and KDM6A mutations in patients with Kabuki syndrome</article-title>
            <source>Am J Med Genet A</source>
            <year>2013</year>
            <volume>161A</volume>
            <issue>9</issue>
            <fpage>2234</fpage>
            <lpage>2243</lpage>
            <pub-id pub-id-type="doi">10.1002/ajmg.a.36072</pub-id>
            <pub-id pub-id-type="pmid">23913813</pub-id>
          </element-citation>
        </ref>
        <ref id="CR43">
          <label>43.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Knapke</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Nagarajan</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Correll</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Kent</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Burns</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Hereditary cancer risk assessment in a pediatric oncology follow-up clinic</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2012</year>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <lpage>89</lpage>
            <pub-id pub-id-type="doi">10.1002/pbc.23283</pub-id>
            <pub-id pub-id-type="pmid">21850677</pub-id>
          </element-citation>
        </ref>
        <ref id="CR44">
          <label>44.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Walsh</surname>
                <given-names>MF</given-names>
              </name>
              <name name-style="western">
                <surname>Wu</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Edmonson</surname>
                <given-names>MN</given-names>
              </name>
              <name name-style="western">
                <surname>Gruber</surname>
                <given-names>TA</given-names>
              </name>
              <name name-style="western">
                <surname>Easton</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Germline mutations in predisposition genes in pediatric cancer</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <volume>373</volume>
            <issue>24</issue>
            <fpage>2336</fpage>
            <lpage>2346</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa1508054</pub-id>
            <pub-id pub-id-type="pmid">26580448</pub-id>
            <pub-id pub-id-type="pmcid">PMC4734119</pub-id>
          </element-citation>
        </ref>
        <ref id="CR45">
          <label>45.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chang</surname>
                <given-names>W</given-names>
              </name>
              <name name-style="western">
                <surname>Brohl</surname>
                <given-names>AS</given-names>
              </name>
              <name name-style="western">
                <surname>Patidar</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Sindiri</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Shern</surname>
                <given-names>JF</given-names>
              </name>
              <name name-style="western">
                <surname>Wei</surname>
                <given-names>JS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Multidimensional ClinOmics for precision therapy of children and adolescent young adults with relapsed and refractory cancer: a report from the center for cancer research</article-title>
            <source>Clin Cancer Res</source>
            <year>2016</year>
            <volume>22</volume>
            <issue>15</issue>
            <fpage>3810</fpage>
            <lpage>3820</lpage>
            <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2717</pub-id>
            <pub-id pub-id-type="pmid">26994145</pub-id>
            <pub-id pub-id-type="pmcid">PMC4970946</pub-id>
          </element-citation>
        </ref>
        <ref id="CR46">
          <label>46.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sakaguchi</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Okuno</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Muramatsu</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Yoshida</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Shiraishi</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia</article-title>
            <source>Nat Genet</source>
            <year>2013</year>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>937</fpage>
            <lpage>941</lpage>
            <pub-id pub-id-type="doi">10.1038/ng.2698</pub-id>
            <pub-id pub-id-type="pmid">23832011</pub-id>
          </element-citation>
        </ref>
        <ref id="CR47">
          <label>47.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Nicolae</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Xi</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Pittaluga</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Abdullaev</surname>
                <given-names>Z</given-names>
              </name>
              <name name-style="western">
                <surname>Pack</surname>
                <given-names>SD</given-names>
              </name>
              <name name-style="western">
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Frequent STAT5B mutations in [gamma][delta] hepatosplenic T-cell lymphomas</article-title>
            <source>Leukemia</source>
            <year>2014</year>
            <volume>28</volume>
            <issue>11</issue>
            <fpage>2244</fpage>
            <lpage>2248</lpage>
            <pub-id pub-id-type="doi">10.1038/leu.2014.200</pub-id>
            <pub-id pub-id-type="pmid">24947020</pub-id>
            <pub-id pub-id-type="pmcid">PMC7701980</pub-id>
          </element-citation>
        </ref>
        <ref id="CR48">
          <label>48.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Amary</surname>
                <given-names>MF</given-names>
              </name>
              <name name-style="western">
                <surname>Damato</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Halai</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Eskandarpour</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Berisha</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Bonar</surname>
                <given-names>F</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2</article-title>
            <source>Nat Genet</source>
            <year>2011</year>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1262</fpage>
            <lpage>1265</lpage>
            <pub-id pub-id-type="doi">10.1038/ng.994</pub-id>
            <pub-id pub-id-type="pmid">22057236</pub-id>
          </element-citation>
        </ref>
        <ref id="CR49">
          <label>49.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pansuriya</surname>
                <given-names>TC</given-names>
              </name>
              <name name-style="western">
                <surname>van Eijk</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>d’Adamo</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>van Ruler</surname>
                <given-names>MA</given-names>
              </name>
              <name name-style="western">
                <surname>Kuijjer</surname>
                <given-names>ML</given-names>
              </name>
              <name name-style="western">
                <surname>Oosting</surname>
                <given-names>J</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome</article-title>
            <source>Nat Genet</source>
            <year>2011</year>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>1256</fpage>
            <lpage>1261</lpage>
            <pub-id pub-id-type="doi">10.1038/ng.1004</pub-id>
            <pub-id pub-id-type="pmid">22057234</pub-id>
            <pub-id pub-id-type="pmcid">PMC3427908</pub-id>
          </element-citation>
        </ref>
        <ref id="CR50">
          <label>50.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ho</surname>
                <given-names>PA</given-names>
              </name>
              <name name-style="western">
                <surname>Alonzo</surname>
                <given-names>TA</given-names>
              </name>
              <name name-style="western">
                <surname>Gerbing</surname>
                <given-names>RB</given-names>
              </name>
              <name name-style="western">
                <surname>Pollard</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Stirewait</surname>
                <given-names>DL</given-names>
              </name>
              <name name-style="western">
                <surname>Hurwitz</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group</article-title>
            <source>Blood</source>
            <year>2009</year>
            <volume>113</volume>
            <issue>26</issue>
            <fpage>6558</fpage>
            <lpage>6566</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2008-10-184747</pub-id>
            <pub-id pub-id-type="pmid">19304957</pub-id>
            <pub-id pub-id-type="pmcid">PMC2943755</pub-id>
          </element-citation>
        </ref>
        <ref id="CR51">
          <label>51.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sturm</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Witt</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Hovestadt</surname>
                <given-names>V</given-names>
              </name>
              <name name-style="western">
                <surname>Khuong-Quang</surname>
                <given-names>DA</given-names>
              </name>
              <name name-style="western">
                <surname>Jones</surname>
                <given-names>DT</given-names>
              </name>
              <name name-style="western">
                <surname>Konermann</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma</article-title>
            <source>Cancer Cell</source>
            <year>2012</year>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>425</fpage>
            <lpage>437</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccr.2012.08.024</pub-id>
            <pub-id pub-id-type="pmid">23079654</pub-id>
          </element-citation>
        </ref>
        <ref id="CR52">
          <label>52.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Chan</surname>
                <given-names>K-M</given-names>
              </name>
              <name name-style="western">
                <surname>Fang</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Gan</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Hashizume</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Yu</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Schroeder</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression</article-title>
            <source>Genes Dev</source>
            <year>2013</year>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>985</fpage>
            <lpage>990</lpage>
            <pub-id pub-id-type="doi">10.1101/gad.217778.113</pub-id>
            <pub-id pub-id-type="pmid">23603901</pub-id>
            <pub-id pub-id-type="pmcid">PMC3656328</pub-id>
          </element-citation>
        </ref>
        <ref id="CR53">
          <label>53.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Khuong-Quang</surname>
                <given-names>D-A</given-names>
              </name>
              <name name-style="western">
                <surname>Buczkowicz</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Rakopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Liu</surname>
                <given-names>XY</given-names>
              </name>
              <name name-style="western">
                <surname>Fontebasso</surname>
                <given-names>AM</given-names>
              </name>
              <name name-style="western">
                <surname>Bouffet</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas</article-title>
            <source>Acta Neuropathol</source>
            <year>2012</year>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>439</fpage>
            <lpage>447</lpage>
            <pub-id pub-id-type="doi">10.1007/s00401-012-0998-0</pub-id>
            <pub-id pub-id-type="pmid">22661320</pub-id>
            <pub-id pub-id-type="pmcid">PMC3422615</pub-id>
          </element-citation>
        </ref>
        <ref id="CR54">
          <label>54.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rao</surname>
                <given-names>Q</given-names>
              </name>
              <name name-style="western">
                <surname>Chen</surname>
                <given-names>JY</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>JD</given-names>
              </name>
              <name name-style="western">
                <surname>Ma</surname>
                <given-names>HH</given-names>
              </name>
              <name name-style="western">
                <surname>Zhou</surname>
                <given-names>HB</given-names>
              </name>
              <name name-style="western">
                <surname>Lu</surname>
                <given-names>ZF</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Renal cell carcinoma in children and young adults: clinicopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up</article-title>
            <source>Int J Surg Pathol</source>
            <year>2011</year>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <lpage>179</lpage>
            <pub-id pub-id-type="doi">10.1177/1066896909354337</pub-id>
            <pub-id pub-id-type="pmid">20034980</pub-id>
          </element-citation>
        </ref>
        <ref id="CR55">
          <label>55.</label>
          <mixed-citation publication-type="other">Gripp K, Baker L, Kandula V, Conard K, Scavina M, Napoli JA, et al. Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation. Am J Med Genet. 2016;Part A 9999A:1–11.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajmg.a.37758</pub-id><pub-id pub-id-type="pmcid">PMC5514817</pub-id><pub-id pub-id-type="pmid">27191687</pub-id></mixed-citation>
        </ref>
        <ref id="CR56">
          <label>56.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Dubuc</surname>
                <given-names>AM</given-names>
              </name>
              <name name-style="western">
                <surname>Remke</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Korshunov</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Northcott</surname>
                <given-names>PA</given-names>
              </name>
              <name name-style="western">
                <surname>Zhan</surname>
                <given-names>SH</given-names>
              </name>
              <name name-style="western">
                <surname>Mendez-Lago</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma</article-title>
            <source>Acta Neuropathol</source>
            <year>2013</year>
            <volume>125</volume>
            <issue>3</issue>
            <fpage>373</fpage>
            <lpage>384</lpage>
            <pub-id pub-id-type="doi">10.1007/s00401-012-1070-9</pub-id>
            <pub-id pub-id-type="pmid">23184418</pub-id>
            <pub-id pub-id-type="pmcid">PMC3580007</pub-id>
          </element-citation>
        </ref>
        <ref id="CR57">
          <label>57.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cheung</surname>
                <given-names>NV</given-names>
              </name>
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Lu</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Parker</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Bahrami</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Tickoo</surname>
                <given-names>SK</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Association of age at diagnosis and genetic mutations in patients with neuroblastoma</article-title>
            <source>JAMA</source>
            <year>2012</year>
            <volume>307</volume>
            <issue>10</issue>
            <fpage>1062</fpage>
            <lpage>1071</lpage>
            <pub-id pub-id-type="doi">10.1001/jama.2012.228</pub-id>
            <pub-id pub-id-type="pmid">22416102</pub-id>
            <pub-id pub-id-type="pmcid">PMC3527076</pub-id>
          </element-citation>
        </ref>
        <ref id="CR58">
          <label>58.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Brenneman</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Field</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Williams</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Doros</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Rossi</surname>
                <given-names>C</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in DICER1 syndrome: a unique variant of the two-hit tumor suppression model</article-title>
            <source>F1000Res</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>214</fpage>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.12688/f1000research.6746.1</pub-id>
            <pub-id pub-id-type="pmcid">PMC4712775</pub-id>
            <pub-id pub-id-type="pmid">26925222</pub-id>
          </element-citation>
        </ref>
        <ref id="CR59">
          <label>59.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Arber</surname>
                <given-names>DA</given-names>
              </name>
              <name name-style="western">
                <surname>Orazi</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Hasserjian</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Thiele</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Borowitz</surname>
                <given-names>MJ</given-names>
              </name>
              <name name-style="western">
                <surname>Le Beau</surname>
                <given-names>MM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia</article-title>
            <source>Blood</source>
            <year>2016</year>
            <volume>127</volume>
            <issue>20</issue>
            <fpage>2391</fpage>
            <lpage>2405</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2016-03-643544</pub-id>
            <pub-id pub-id-type="pmid">27069254</pub-id>
          </element-citation>
        </ref>
        <ref id="CR60">
          <label>60.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ernst</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Score</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Deininger</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Hidalgo-Curtis</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Lackie</surname>
                <given-names>P</given-names>
              </name>
              <name name-style="western">
                <surname>Ershler</surname>
                <given-names>WB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia</article-title>
            <source>Br J Haematol</source>
            <year>2011</year>
            <volume>153</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <lpage>46</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08457.x</pub-id>
            <pub-id pub-id-type="pmid">21391972</pub-id>
          </element-citation>
        </ref>
        <ref id="CR61">
          <label>61.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Masetti</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Pigazzi</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Togni</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Astolfi</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Indio</surname>
                <given-names>V</given-names>
              </name>
              <name name-style="western">
                <surname>Manara</surname>
                <given-names>E</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype</article-title>
            <source>Blood</source>
            <year>2013</year>
            <volume>121</volume>
            <issue>17</issue>
            <fpage>3469</fpage>
            <lpage>3472</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2012-11-469825</pub-id>
            <pub-id pub-id-type="pmid">23407549</pub-id>
          </element-citation>
        </ref>
        <ref id="CR62">
          <label>62.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Laé</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Ahn</surname>
                <given-names>EH</given-names>
              </name>
              <name name-style="western">
                <surname>Mercado</surname>
                <given-names>GE</given-names>
              </name>
              <name name-style="western">
                <surname>Chuai</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Edgar</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Pawel</surname>
                <given-names>BR</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas</article-title>
            <source>J Pathol</source>
            <year>2007</year>
            <volume>212</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <lpage>151</lpage>
            <pub-id pub-id-type="doi">10.1002/path.2170</pub-id>
            <pub-id pub-id-type="pmid">17471488</pub-id>
          </element-citation>
        </ref>
        <ref id="CR63">
          <label>63.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Williamson</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Missiaglia</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>de Reyniès</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Pierron</surname>
                <given-names>G</given-names>
              </name>
              <name name-style="western">
                <surname>Thuille</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Palenzuela</surname>
                <given-names>G</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Fusion gene–negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <volume>28</volume>
            <issue>13</issue>
            <fpage>2151</fpage>
            <lpage>2158</lpage>
            <pub-id pub-id-type="doi">10.1200/JCO.2009.26.3814</pub-id>
            <pub-id pub-id-type="pmid">20351326</pub-id>
          </element-citation>
        </ref>
        <ref id="CR64">
          <label>64.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Skapek</surname>
                <given-names>SX</given-names>
              </name>
              <name name-style="western">
                <surname>Anderson</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Barr</surname>
                <given-names>FG</given-names>
              </name>
              <name name-style="western">
                <surname>Bridge</surname>
                <given-names>JA</given-names>
              </name>
              <name name-style="western">
                <surname>Gastier-Foster</surname>
                <given-names>JM</given-names>
              </name>
              <name name-style="western">
                <surname>Parham</surname>
                <given-names>DM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2013</year>
            <volume>60</volume>
            <issue>9</issue>
            <fpage>1411</fpage>
            <lpage>1417</lpage>
            <pub-id pub-id-type="doi">10.1002/pbc.24532</pub-id>
            <pub-id pub-id-type="pmid">23526739</pub-id>
            <pub-id pub-id-type="pmcid">PMC4646073</pub-id>
          </element-citation>
        </ref>
        <ref id="CR65">
          <label>65.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ladanyi</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Lui</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Antonescu</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Krause-Boehm</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Meindl</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Argani</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25</article-title>
            <source>Oncogene</source>
            <year>2001</year>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <lpage>57</lpage>
            <pub-id pub-id-type="doi">10.1038/sj.onc.1204074</pub-id>
            <pub-id pub-id-type="pmid">11244503</pub-id>
          </element-citation>
        </ref>
        <ref id="CR66">
          <label>66.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Delattre</surname>
                <given-names>O</given-names>
              </name>
              <name name-style="western">
                <surname>Zucman</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Plougastel</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Desmaze</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Melot</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Peter</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours</article-title>
            <source>Nature</source>
            <year>1992</year>
            <volume>359</volume>
            <issue>6391</issue>
            <fpage>162</fpage>
            <lpage>165</lpage>
            <pub-id pub-id-type="doi">10.1038/359162a0</pub-id>
            <pub-id pub-id-type="pmid">1522903</pub-id>
          </element-citation>
        </ref>
        <ref id="CR67">
          <label>67.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Parker</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Mohankumar</surname>
                <given-names>KM</given-names>
              </name>
              <name name-style="western">
                <surname>Punchihewa</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Weinlich</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Dalton</surname>
                <given-names>JD</given-names>
              </name>
              <name name-style="western">
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>C11orf95-RELA fusions drive oncogenic NF-[kgr]B signalling in ependymoma</article-title>
            <source>Nature</source>
            <year>2014</year>
            <volume>506</volume>
            <issue>7489</issue>
            <fpage>451</fpage>
            <lpage>455</lpage>
            <pub-id pub-id-type="doi">10.1038/nature13109</pub-id>
            <pub-id pub-id-type="pmid">24553141</pub-id>
            <pub-id pub-id-type="pmcid">PMC4050669</pub-id>
          </element-citation>
        </ref>
        <ref id="CR68">
          <label>68.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pajtler Kristian</surname>
                <given-names>W</given-names>
              </name>
              <name name-style="western">
                <surname>Witt</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Sill</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Jones</surname>
                <given-names>DT</given-names>
              </name>
              <name name-style="western">
                <surname>Hovestadt</surname>
                <given-names>V</given-names>
              </name>
              <name name-style="western">
                <surname>Kratochwil</surname>
                <given-names>F</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups</article-title>
            <source>Cancer Cell</source>
            <year>2015</year>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>728</fpage>
            <lpage>743</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccell.2015.04.002</pub-id>
            <pub-id pub-id-type="pmid">25965575</pub-id>
            <pub-id pub-id-type="pmcid">PMC4712639</pub-id>
          </element-citation>
        </ref>
        <ref id="CR69">
          <label>69.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bosse</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Maris</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations</article-title>
            <source>Cancer</source>
            <year>2016</year>
            <volume>122</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <lpage>33</lpage>
            <pub-id pub-id-type="doi">10.1002/cncr.29706</pub-id>
            <pub-id pub-id-type="pmid">26539795</pub-id>
            <pub-id pub-id-type="pmcid">PMC4707066</pub-id>
          </element-citation>
        </ref>
        <ref id="CR70">
          <label>70.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Attiyeh</surname>
                <given-names>EF</given-names>
              </name>
              <name name-style="western">
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name name-style="western">
                <surname>Mossé</surname>
                <given-names>YP</given-names>
              </name>
              <name name-style="western">
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name name-style="western">
                <surname>Winter</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Khazi</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Chromosome 1p and 11q deletions and outcome in neuroblastoma</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <volume>353</volume>
            <issue>21</issue>
            <fpage>2243</fpage>
            <lpage>2253</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMoa052399</pub-id>
            <pub-id pub-id-type="pmid">16306521</pub-id>
          </element-citation>
        </ref>
        <ref id="CR71">
          <label>71.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>López-Terrada</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Gunaratne</surname>
                <given-names>PH</given-names>
              </name>
              <name name-style="western">
                <surname>Adesina</surname>
                <given-names>AM</given-names>
              </name>
              <name name-style="western">
                <surname>Pulliam</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Hoang</surname>
                <given-names>DM</given-names>
              </name>
              <name name-style="western">
                <surname>Nguyen</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors</article-title>
            <source>Hum Pathol</source>
            <year>2009</year>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>783</fpage>
            <lpage>794</lpage>
            <pub-id pub-id-type="doi">10.1016/j.humpath.2008.07.022</pub-id>
            <pub-id pub-id-type="pmid">19200579</pub-id>
          </element-citation>
        </ref>
        <ref id="CR72">
          <label>72.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Northcott</surname>
                <given-names>PA</given-names>
              </name>
              <name name-style="western">
                <surname>Korshunov</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Witt</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Hielscher</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Eberhart</surname>
                <given-names>CG</given-names>
              </name>
              <name name-style="western">
                <surname>Mack</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Medulloblastoma comprises four distinct molecular variants</article-title>
            <source>J Clin Oncol</source>
            <year>2011</year>
            <volume>29</volume>
            <issue>11</issue>
            <fpage>1408</fpage>
            <lpage>1414</lpage>
            <pub-id pub-id-type="doi">10.1200/JCO.2009.27.4324</pub-id>
            <pub-id pub-id-type="pmid">20823417</pub-id>
            <pub-id pub-id-type="pmcid">PMC4874239</pub-id>
          </element-citation>
        </ref>
        <ref id="CR73">
          <label>73.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kilday</surname>
                <given-names>J-P</given-names>
              </name>
              <name name-style="western">
                <surname>Mitra</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Domerg</surname>
                <given-names>C</given-names>
              </name>
              <name name-style="western">
                <surname>Ward</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Andreiuolo</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Osteso-Ibanez</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective european clinical trial cohort analysis on behalf of the Children’s Cancer Leukaemia Group (CCLG), Société Française d’Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)</article-title>
            <source>Clin Cancer Res</source>
            <year>2012</year>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>2001</fpage>
            <lpage>2011</lpage>
            <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2489</pub-id>
            <pub-id pub-id-type="pmid">22338015</pub-id>
          </element-citation>
        </ref>
        <ref id="CR74">
          <label>74.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Olsen</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Gorunova</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Meling</surname>
                <given-names>TR</given-names>
              </name>
              <name name-style="western">
                <surname>Micci</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Scheie</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Due-Tonnessen</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic characterization of ependymomas reveals 6q loss as the most common aberration</article-title>
            <source>Oncol Rep</source>
            <year>2014</year>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>483</fpage>
            <lpage>490</lpage>
            <pub-id pub-id-type="pmid">24939246</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2014.3271</pub-id>
            <pub-id pub-id-type="pmcid">PMC4091878</pub-id>
          </element-citation>
        </ref>
        <ref id="CR75">
          <label>75.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rousseau</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Idbaih</surname>
                <given-names>A</given-names>
              </name>
              <name name-style="western">
                <surname>Ducray</surname>
                <given-names>F</given-names>
              </name>
              <name name-style="western">
                <surname>Criniere</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Fevre-Montange</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Jouvet</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade</article-title>
            <source>J Neurooncol</source>
            <year>2010</year>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>353</fpage>
            <lpage>364</lpage>
            <pub-id pub-id-type="doi">10.1007/s11060-009-0039-6</pub-id>
            <pub-id pub-id-type="pmid">19865800</pub-id>
          </element-citation>
        </ref>
        <ref id="CR76">
          <label>76.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Marko</surname>
                <given-names>N</given-names>
              </name>
              <name name-style="western">
                <surname>Weil</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The molecular biology of WHO Grade II gliomas</article-title>
            <source>Neurosurg Focus</source>
            <year>2013</year>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>E1</fpage>
            <pub-id pub-id-type="doi">10.3171/2012.12.FOCUS12283</pub-id>
            <pub-id pub-id-type="pmid">23373446</pub-id>
          </element-citation>
        </ref>
        <ref id="CR77">
          <label>77.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gerald</surname>
                <given-names>WL</given-names>
              </name>
              <name name-style="western">
                <surname>Rosai</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Ladanyi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1995</year>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>1028</fpage>
            <lpage>1032</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.92.4.1028</pub-id>
            <pub-id pub-id-type="pmid">7862627</pub-id>
            <pub-id pub-id-type="pmcid">PMC42630</pub-id>
          </element-citation>
        </ref>
        <ref id="CR78">
          <label>78.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jackson</surname>
                <given-names>EM</given-names>
              </name>
              <name name-style="western">
                <surname>Sievert</surname>
                <given-names>AJ</given-names>
              </name>
              <name name-style="western">
                <surname>Gai</surname>
                <given-names>X</given-names>
              </name>
              <name name-style="western">
                <surname>Hakonarson</surname>
                <given-names>H</given-names>
              </name>
              <name name-style="western">
                <surname>Judkins</surname>
                <given-names>AR</given-names>
              </name>
              <name name-style="western">
                <surname>Tooke</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors</article-title>
            <source>Clin Cancer Res</source>
            <year>2009</year>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>1923</fpage>
            <lpage>1930</lpage>
            <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2091</pub-id>
            <pub-id pub-id-type="pmid">19276269</pub-id>
            <pub-id pub-id-type="pmcid">PMC2668138</pub-id>
          </element-citation>
        </ref>
        <ref id="CR79">
          <label>79.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Torchia</surname>
                <given-names>J</given-names>
              </name>
              <name name-style="western">
                <surname>Picard</surname>
                <given-names>D</given-names>
              </name>
              <name name-style="western">
                <surname>Lafay-Cousin</surname>
                <given-names>L</given-names>
              </name>
              <name name-style="western">
                <surname>Hawkins</surname>
                <given-names>CE</given-names>
              </name>
              <name name-style="western">
                <surname>Kim</surname>
                <given-names>SK</given-names>
              </name>
              <name name-style="western">
                <surname>Letourneau</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis</article-title>
            <source>Lancet Oncol</source>
            <year>2015</year>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>569</fpage>
            <lpage>582</lpage>
            <pub-id pub-id-type="doi">10.1016/S1470-2045(15)70114-2</pub-id>
            <pub-id pub-id-type="pmid">25882982</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
